INTRODUCTION
============

Diabetes is a disease of epidemic proportion \[[@R1],[@R2]\], but glycemic control is rarely optimized and some therapeutic interventions cause hypoglycemia, weight gain and possibly exacerbate cardiovascular (CVD) risk \[[@R3]\]. Data from large studies indicate that restoration of glycemic control when coupled with weight loss can improve hypertension, dyslipidemia, and other CVD risk markers \[[@R4]-[@R6]\].

Exenatide (synthetic exendin-4) is a glucagon-like peptide-1 (GLP-1) receptor agonist that has been developed as a first-in-class diabetes therapy. This review presents an overview of the evolution of exenatide as a treatment for type 2 diabetes (T2DM) from seminal preclinical discoveries, clinical pharmacology investigations, and phase 3 clinical trials (Fig. **[1](#F1){ref-type="fig"}**). By building upon early observations of antihyperglycemic actions by GLP-1 and Gila monster exendin-4, exenatide was successfully developed into a diabetes therapeutic agent with a broad range of beneficial cardiometabolic effects and an acceptable tolerability profile. A twice daily (BID) exenatide formulation is currently approved for use in patients with T2DM in the U.S., E.U., Japan, and other countries. A once weekly (QW) exenatide formulation is also currently approved for use in the U.S., E.U., and Japan, while a once-monthly formulation is undergoing clinical testing.

INCRETINS
=========

The \'incretin effect\' (Fig. **[2A](#F2){ref-type="fig"}**) was originally described as the observation that oral glucose stimulates insulin secretion to a greater extent than an intravenous infusion of glucose \[[@R7]-[@R11]\]. Later, ingestion of various solid foods was also found to stimulate this physiological response to nutrient ingestion. GLP-1 and glucose-dependent insulinotrophic polypeptide (ie, gastric inhibitory polypeptide \[GIP\]) are the gut hormones primarily responsible for the incretin effect. In healthy, normoglycemic adults the contributions of GLP-1 and GIP to the insulin secretory response to elevated circulating glucose concentrations (nutrient ingestion) are estimated to be 73% of the total response. Because of its pleiotropic metabolic effects and for the reasons explained below, GLP-1 quickly became the primary focus of drug development efforts for treating diabetes (Fig. **[2B](#F2){ref-type="fig"}**).

The GLP-1 Receptor and GLP-1
----------------------------

The GLP-1 receptor (GLP-1R) is a seven-transmembrane domain, G-protein coupled receptor expressed in pancreatic periductal- and β-cells, kidney, heart and blood vessels, stomach, small and large intestine, lung, and brain \[[@R12]-[@R16]\] The physiology of the GLP-1R and its ligand have been extensively explored within the context of glucose homeostasis using GLP-1R(-/-) knockout (KO) mice \[[@R17]-[@R24]\]. GLP-1R KO mice have elevated blood glucose concentrations following an oral glucose challenge, coupled with lower than normal plasma insulin concentrations \[[@R17],[@R19],[@R20]\]. GLP-1 fails to stimulate insulin release from isolated pancreatic islets from GLP-1R KO mice, in sharp contrast to the 2-fold insulin stimulation in islets from normal mice and despite equivalent insulin content in islets from both mouse strains \[[@R18]\]. Similar results were observed using perfused pancreata \[[@R19]\]. In addition, De León *et al.* \[[@R24]\] examined β-cell mass regeneration after GLP-1R KO mice were 70% pancreatectomized. Five weeks post-surgery, β-cell mass was not significantly different between wild-type pancreatectomized or sham-operated mice. However, in GLP-1R KO mice, β-cell mass remained significantly lower in pancreatectomized versus sham-operated animals, confirming a role for GLP-1 in pancreatic islet regeneration in the mouse.

GLP-1, the only endogenous ligand for the GLP-1R, is rapidly secreted by the L-cells of the intestinal mucosa in response to nutrient ingestion \[[@R25]\]. This peptide hormone enhances glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon secretion, slows gastric emptying, and reduces food intake \[[@R25]-[@R31]\]. In rodent models, GLP-1 treatment is associated with pancreatic islet neogenesis, β-cell proliferation, and increased β-cell mass \[[@R32]-[@R34]\].

Initially, a role for GLP-1 in ameliorating diabetes pathophysiology was explored using continuous infusion techniques to increase circulating GLP-1 concentrations \[[@R35]\]. In patients with T2DM, 6 weeks of continuous GLP-1 infusion significantly reduced HbA~1c~, fasting glucose, and post-prandial glucose excursions compared with placebo (PBO) infusion (Fig. **[3](#F3){ref-type="fig"}**). GLP-1 infusion also improved β-cell sensitivity to ambient glucose by 77% compared with baseline, and re-established a more normal pattern of both first- and second-phase insulin secretion. Gastric emptying was slowed and patients lost weight. GLP-1 reduced sensations of hunger, i.e., enhanced satiety and fullness, and reduced prospective food intake; these effects were absent with PBO infusion. In another study, intravenous infusion of GLP-1 prior to, and during, a glucose challenge in patients with T2DM was associated with an insulinotropic effect on both first- and second-phase insulin secretion, augmentation of glucose disappearance rates, and suppression of circulating glucagon levels \[[@R36]\]. Despite these positive effects, GLP-1 augmentation as a strategy to treat diabetes was deemed impractical, because GLP-1 is rapidly degraded in the circulatory system, by the enzyme dipeptidyl peptidase-IV (DPP-4), with a half-life of less than 2 minutes \[[@R37],[@R38]\].

EXENDIN-4
=========

Exendin-4, the naturally occurring form of exenatide, was investigated as a potential ligand for the GLP-1R and a possible diabetes therapy after a number of nonclinical discoveries. Exendin-4 was originally isolated from the salivary secretions of the lizard *Heloderma suspectum* (Gila monster) \[[@R39],[@R40]\]. Exendin-4 has a 53% amino acid sequence homology with mammalian GLP-1 (Fig. **[4](#F4){ref-type="fig"}**) \[[@R39],[@R40]\]. However, mammalian GLP-1 is processed from the proglucagon gene in L-cells in the small intestine, whereas lizard exendin-4 is transcribed from a different gene, not the Gila monster homologue of the mammalian proglucagon \[[@R41]\]. The second seminal discovery was that exendin-4 is resistant to degradation by DPP-4, the enzyme responsible for rapidly degrading endogenous GLP-1 \[[@R37],[@R38]\]. Third, although exendin-4 is not an analogue of GLP-1, exendin-4 and GLP-1 share many glucoregulatory actions mediated by the GLP-1 receptor \[[@R42]\]. The pancreatic GLP-1 receptor binds exendin-4 and GLP-1 with equal affinity *in vitro*, and both peptides stimulate the receptor equipotently \[[@R42]-[@R45]\]. Hence, exendin-4 is a GLP-1R agonist.

Actions shared by exendin-4 and GLP-1 in non-human studies include reduction of hyperglycemia, glucose-dependent enhancement of insulin secretion, glucose-dependent suppression of inappropriately high glucagon secretion, slowing of gastric emptying, and reduction of food intake, often with body weight reduction or blunting of weight gain \[[@R39],[@R44],[@R46]-[@R49]\]. In both *in vitro* and *in vivo* preclinical models, exendin-4 promoted β-cell proliferation and islet neogenesis from precursor cells \[[@R33],[@R50]-[@R56]\]. Further, as a result of its enhanced pharmacokinetics compared to GLP-1, exendin-4 demonstrated very high *in vivo* potency relative to native GLP-1 \[[@R44],[@R46],[@R56]\].

Exendin-4 and Insulin-Secreting β-cells in Animal Models of Diabetes
--------------------------------------------------------------------

The actions of exendin-4 on insulin secretion from pancreatic β-cell has been studied in a number of animal models of T2DM. T2DM is characterized by progressive loss of β-cell function \[[@R3],[@R4],[@R5],[@R58],[@R59]\]. The emergence of overt T2DM is precipitated by the failure of pancreatic β cells to secrete adequate amounts of insulin to compensate for insulin resistance in peripheral tissues, primarily liver and muscle. Further, T2DM is characterized by the emergence of post-prandial- and subsequently, fasting- hyperglycemia. In the liver, insulin resistance is manifested by glucose overproduction during the basal state despite fasting hyperinsulinemia, combined with impaired hepatic response to the normal elevation in postprandial insulin. In muscle, insulin resistance manifests as impaired postprandial glucose uptake.

A number of preclinical reports demonstrated exendin-4-mediated restoration of function and mass of insulin-secreting islets in the rodent pancreas \[[@R32],[@R50],[@R52]-[@R56]\]. These models of T2DM and obesity include the obese (*ob/ob*) mouse that is deficient in the hormone leptin and expresses insulin resistance and impaired insulin tolerance, the *db/db* mouse that has a defect in leptin signaling and expresses insulin resistance, hypertriglyceridemia and has impaired glucose tolerance, the partial-pancreatectomized rodent model (rats or mice), the Goto-Kakizaki rat that is genetically predisposed to a neonatal β-cell mass deficiency, the insulin-resistant obese *fa/fa* diabetic Zucker rat, the nondiabetic insulin-resistant obese *fa/fa* Zucker rat, and spontaneously-diabetic Rhesus monkeys. For example, in mice genetically predisposed to develop diabetes (*db/db*), exendin-4 increased β-cell proliferation and islet mass, ameliorated the normal development of hyperglycemia, improved insulin secretion, and reduced HbA~1c~. Exendin-4 also blocked β-cell apoptosis, increased pancreatic expression of transcription factors, and enhanced islet neogenesis. Due to the difficulty of reproducing this type of experiment in humans, it is not known whether the same mechanism is active in patients with T2DM.

Glucose-dependent insulinotropism, the ability of agents to stimulate insulin secretion during euglycemia or hyperglycemia, but not during hypoglycemia, was elucidated in some of the preclinical models of diabetes described above \[[@R39],[@R44],[@R49]\]. For example, in diabetic *db/db* mice, chronic exendin-4 administration resulted in fasting serum insulin concentrations notably higher than with vehicle treatment under conditions of hyperglycemia \[[@R44]\]. HbA~1c~ and fasting glucose concentrations were significantly reduced, but did not quite reach normoglycemic levels, with no evidence of hypoglycemia. Another preclinical study investigated whether the previously-described effects of exendin-4 on insulin sensitivity, appetite, and body weight were distinct from its antihyperglycemic effects \[[@R53]\]. In this study, exendin-4 increased β-cell mass to a greater extent in nondiabetic insulin-resistant obese *fa/fa* Zucker rats than would be expected in animals of comparable insulin-resistance, suggesting a direct trophic effect of exendin-4 on pancreatic islet neogenesis, independent of improvements in metabolic parameters. This study was the first to show that exendin-4 could improve insulin sensitivity in an environment of insulin resistance, partly due to reductions in food intake and partly independent of changes in body weight and ambient glycemia.

### Exendin-4 and Body Weight in Animal Models of Diabetes and/or Obesity

In nonclinical diabetes models, weight loss or blunted weight gain are consistently associated with exendin-4 treatments \[[@R39],[@R46],[@R47],[@R48]\]. Studies have extended these findings to include obese, normoglycemic animal models. For example, exendin-4 treatment for 56 days reduced food intake and slowed weight gain in obese *fa/fa* Zucker rats \[[@R47]\]. Corresponding reductions in HbA~1c~, fasting glucose, and fasting insulin also occurred. In a later study, acute exendin-4 administration dose-dependently suppressed food intake in normoglycemic mice and rats fed a high fat diet, while chronic, continuous exendin-4 infusion significantly slowed body weight gain, decreased fat mass, and spared lean tissue \[[@R48]\]. Food intake, total cholesterol, triglycerides and insulin levels were all significantly reduced. These data suggest that exendin-4 has an effect on metabolic pathways regulating food ingestion.

EXENATIDE (SYNTHETIC EXENDIN-4) CLINICAL PHARMACOLOGY AND EXPLORATORY INVESTIGATIONS
====================================================================================

Overview
--------

Clinical pharmacology studies have been conducted using synthetic exendin-4 (exenatide) administered as subcutaneous injections or intravenous infusions. These studies have identified the appropriate dosing approach for clinical use, and explored the mechanisms of action in humans. Initial dosing strategies explored single bolus, continuous infusion, and twice (BID) and thrice (TID) daily subcutaneous administration before meals. In these studies, subcutaneous injections of 10-mcg exenatide twice daily (ExBID) demonstrated a consistent pattern of pharmacokinetics and pharmacodynamic responses, with transient, mild-to-moderate nausea as the primary side effect \[[@R60]-[@R65]\]. There was a minimal dependence of exenatide pharmacokinetic profiles on body weight, supporting development of a fixed dosage regimen for ExBID \[[@R59],[@R62]\]. These studies also found utility in starting patients on a 5-mcg exenatide BID dose, generally for 4 weeks, before increasing to the maintenance dose of 10-mcg BID \[[@R66]\]. This graduated approach mitigated much of the nausea and vomiting observed when initiating directly with the 10-mcg BID dose.

The mechanisms of action elucidated in nonclinical experiments with exendin-4 were largely confirmed in early human studies in both healthy individuals and in patients with type 2 diabetes. In patients with T2DM, exenatide slowed gastric emptying; reduced fasting hyperglycemia and hyperglucagonemia; stimulated glucose-dependent insulin secretion (pancreatic β-cell function); attenuated post-prandial excursions of glucose, insulin, and glucagon; inhibited food intake; and reduced body weight. The integrated effects of these mechanisms are likely important for the clinical efficacy of ExBID.

Studies on Gastric Emptying and Satiety
---------------------------------------

The effects of exenatide on gastric emptying in patients with T2DM are best understood within the context of the important role the rate of nutrient delivery from the stomach to the small intestine plays in the extent of post-prandial glucose excursions \[[@R67],[@R68]\]. One of the main confounders in understanding the pathophysiology of gastric emptying in diabetes is hyperglycemia itself, as elevated glucose concentrations in healthy individuals slow the rate of gastric emptying in order to moderate postprandial glucose excursions \[[@R67]\]. Thus the gastric emptying rate in the face of diabetic hyperglycemia may be considered pathophysiological, as gastric emptying is relatively accelerated in patients with diabetes, compared with the usually expected slowing of gastric emptying that occurs in healthy individuals under similar hyperglycemic conditions. In patients with T2DM (without severe autonomic neuropathy), gastric emptying rates are often accelerated compared with healthy individuals. Conversely, patients with T2DM and severe autonomic neuropathy often have reduced gastric emptying (gastroparesis).

For exenatide, slowing of gastric emptying and reduced food intake were first established as important mechanisms-of-action in nonclinical experiments \[[@R44],[@R47]\]. Later, clinical pharmacology studies confirmed slowed gastric emptying in patients with T2DM given various exenatide doses including clinically-relevant doses \[[@R59]-[@R62],[@R69],[@R70]\]. Using scintigraphy, 5-days of ExBID was shown to slow gastric emptying of both the solid and the liquid components of a meal \[[@R70]\]. The T~50~ (time to achieve 50% stomach emptying) for solid meal components was 169 minutes, significantly slower than the T~50~ of 60 minutes for PBO. The T~50~ for liquid meal components was 114 minutes, also significantly slower than the T~50~ of 34 minutes for PBO. Thus, ExBID increased the T~50~3-fold for both solids and liquids compared with PBO.

Clinical studies have also documented a significant reduction of food intake and patient reports of increased satiety after exenatide administration in both normo- and hyperglycemic individuals \[[@R69],[@R71],[@R72]\]. In lean (mean BMI 25 kg/m^2^), healthy young adults, bolus injections of 10 mcg exenatide reduced caloric intake, overall food intake, and ingestion of proteins, carbohydrates, and total fat, compared with placebo \[[@R71]\]. When exenatide was injected 60 minutes prior to a standardized meal, mean caloric intake was significantly lower (463 kcal compared with 672 kcal for placebo). Post-prandial glucose concentrations at 60 and 120 minutes after meals were also reduced. In another study enrolling healthy volunteers, exenatide acutely reduced food intake and slowed gastric emptying \[[@R72]\]. Subjects consumed 19% fewer calories at a free-choice buffet lunch with exenatide than with placebo (867±79 kcal versus 1,075±93 kcal, respectively; p=0.012). Further, T2DM patients administered exenatide had significantly reductions in caloric intake, postprandial triglycerides, and body weight, compared to treatment with the DPP-4 inhibitor sitagliptin \[[@R69]\]. Exenatide reduced total caloric intake by -134±97 kcal compared with an increase of +130±97 kcal with sitagliptin.

Integrated Effects of Exenatide on Glycemia
-------------------------------------------

In patients with T2DM, exenatide rapidly lowers both fasting and postprandial plasma glucose by multiple mechanisms \[[@R60]-[@R61],[@R69],[@R72],[@R74]\]. In the postprandial state, exenatide slows gastric emptying to modulate the rate of nutrient absorption and moderate the extent of postprandial glucose excursions. Representative dose-response profiles found during these early exenatide clinical studies for the simultaneous changes in glucose, insulin, and glucagon occurring after an exenatide injection demonstrated these actions at clinically-relevant doses (Fig. **[5](#F5){ref-type="fig"}**). In two separate early-stage, 28-day clinical trials, exenatide also dose-dependently reduced HbA~1c~ \[[@R60],[@R63]\].

Two other clinical pharmacology studies investigated the relative contributions of slowed gastric emptying, enhanced insulin secretion, glucagon suppression, and splanchnic and peripheral glucose metabolism on postprandial glucose excursions in patients with T2DM after intravenous exenatide administration \[[@R75],[@R76]\]. Glucose retained within the splanchnic bed consists of glucose taken-up and stored by the liver, glucose metabolized by gastrointestinal tissues, and glucose remaining in the gastrointestinal tract. Infusion of exenatide with an oral glucose bolus or a mixed meal attenuated the rate of glucose appearance in the circulatory system. Exenatide decreased endogenous glucose release from the liver by approximately 45% and increased glucose retention in the splanchnic area. However, exenatide did not increase tissue sensitivity to insulin, nor did it alter the rate of total body glucose disposal.

In multiple clinical pharmacology studies in patients with T2DM, exenatide was shown to modulate fasting serum insulin and glucagon in a manner dependent upon exenatide dose and ambient glucose concentrations \[[@R60]-[@R62],[@R64],[@R69],[@R77]-[@R80]\]. Both acute and chronic exenatide therapy improved β-cell secretory function (i.e., insulin secretion in response to hyperglycemia). In patients with T2DM with a blunted first phase insulin secretory response after acute elevation of blood glucose levels, intravenous exenatide in the therapeutic range restored the normal first phase insulin secretory response \[[@R79]\]. Exenatide also augmented the second-phase insulin secretory response. Of note, the overweight patients with T2DM enrolled in this study had a mean HbA~1c~ of 6.6%, indicating good glycemic control at baseline.

The ability of exenatide to dose-dependently suppress inappropriately-elevated glucagon secretion was demonstrated in patients with T2DM in a number of clinical pharmacology studies \[[@R61],[@R62],[@R63],[@R69],[@R80]\]. Exenatide-mediated reductions in plasma glucagon concentrations under fasting conditions support the hypothesis that suppression of glucagon secretion is not merely a consequence of the slowing of nutrient presentation to the small intestine (gastric emptying).

Degn *et al.* \[[@R81]\] explored glucose-dependent insulin secretion and the counter-regulatory response to hypoglycemia in healthy volunteers given an intravenous infusion of exenatide or PBO (Fig. **[6](#F6){ref-type="fig"}**). In the presence of euglycemic hyperinsulinemia, insulin secretory rates with exenatide were significantly (3.5-fold) higher than with PBO. During hypoglycemia, insulin secretory rates declined similarly and rapidly in both groups. Glucagon was markedly more suppressed with exenatide than with PBO (\~50% lower) under conditions of euglycemia. During worsening of hypoglycemia, glucagon increased progressively with both treatments, but to a significantly greater extent with exenatide. Plasma glucose recovery time was equivalent for both treatments. During the recovery interval, glucagon response was equivalent in both treatment arms. Circulating levels of cortisol, epinephrine, norepinephrine, and growth hormone were similar between treatment arms, indicating preservation of the counter-regulatory response to hypoglycemia during exenatide exposure.

Effects of Exenatide on CVD Risk Markers and in Fatty Liver Disease
-------------------------------------------------------------------

Exenatide has been shown to have beneficial effects on cardiovascular biomarkers. Acute exenatide administration suppressed postprandial excursions of pro-atherogenic lipid and lipoprotein in overweight/obese adults with impaired glucose tolerance or recent onset T2DM \[[@R82],[@R83]\]. Fifty-seven percent of these patients were being treated with statins for dyslipidemia. However, one injection of exenatide was still able to markedly reduce postprandial elevation of triglycerides, apolipoprotein B-48, apolipoprotein-CIII, remnant-like particles-cholesterol and remnant-like particles-triglyceride compared with baseline. In another study, ExBID significantly improved markers of oxidative stress (prostaglandin F2α) and cardiovascular inflammation (high sensitivity C-reactive protein \[hsCRP\]), independent of baseline HbA~1c~, body weight, and BMI \[[@R84]\].

ExBID also had beneficial effects on liver fat content in patients with type 2 diabetes, in whom nonalcoholic fatty liver disease is prevalent \[[@R85]\]. ExBID significantly increased plasma adiponectin, reduced hepatic fat content (from mean 12.1% to 4.7%), and plasma triglyceride concentrations (-38%), despite no significant change in body weight. In addition, the hepatic injury biomarkers aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were significantly decreased by ExBID, suggesting beneficial effects on fatty liver disease.

EXENATIDE BID EFFICACY IN LATE STAGE CLINICAL TRIALS
====================================================

Overview
--------

In controlled trials ranging in treatment duration from 12 to 52 weeks where HbA~1c~ reduction was a primary endpoint, ExBID as monotherapy and in various combinations with MET, SFU, TZD, and insulins reduced mean HbA~1c~ by -0.8% to -1.7% in T2DM patients with mean baseline HbA~1c~ values ranging from 7.5% to 10.2% (Tables **[1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**) \[[@R86]-[@R120]\].[1](#FN1){ref-type="fn"},[2](#FN2){ref-type="fn"} The percentage of patients with T2DM achieving HbA~1c~ values ≤7% with ExBID ranged from 20% to 79%, depending upon the baseline characteristics of the patient populations, their concomitant medications, and the active treatment regimen. In a study where weight reduction was the primary endpoint, patients with T2DM with a mean baseline HbA~1c~ of 7.7% still had mean HbA~1c~ reductions of -0.6% more than PBO when ExBID was added to intensive lifestyle modification \[[@R121]\].

Meta-analyses of large clinical trials have demonstrated a positive correlation between baseline HbA~1c~ and the magnitude of HbA~1c~ response to therapy, independent of drug class or mechanism of action \[[@R122],[@R123]\]. Consistent with these reports, ExBID-treated patients with a high mean baseline HbA~1c~ of 10.2% had a mean HbA~1c~ change of -1.74% after 24 weeks of treatment \[[@R86]\]. This cohort was insulin-naive, had a mean diabetes duration of 9 years, and had failed to maintain glycemic control during treatment with MET plus SFU. In a study that allowed up-titration of insulin glargine to help achieve glycemic goals in all treatment arms, patients with a more moderate mean baseline HbA~1c~ of 8.3% had a mean HbA~1c~ reduction of -1.74% after 30 weeks of ExBID treatment \[[@R90]\]. Notably, these patients had a longer mean diabetes duration (12 years) than in the Bergenstal *et al.* \[[@R86]\] study and had failed to achieve glycemic control on more aggressive therapy (insulin glargine with or without MET±TZD). A *post hoc* analysis of pooled data from 17 ExBID clinical trials encompassing 2,096 patients found reductions in glycemic parameters and body weight across a wide range of background antidiabetes therapies \[[@R124]\].

Body weight reductions have consistently been associated with ExBID therapy, despite wide variability in T2DM duration and patient characteristics at baseline, concomitant medications, and study designs (Tables **[1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**) \[[@R86]-[@R120]\].[1](#FN1){ref-type="fn"},[2](#FN2){ref-type="fn"} Mean weight change with ExBID ranged from -1.2 kg to -8.0 kg in exposure periods ranging from 12 to 52 weeks. The proportion of ExBID-treated patients who had reductions in both HbA~1c~ and body weight was reported in two controlled trials: 66% versus 36% with PBO \[[@R99]\] and 71% versus 54% with PBO \[[@R107]\]. A small percentage of patients may gain weight while receiving exenatide therapy.

Pivotal Clinical Trials, Pivotal Trial Extensions, and Monotherapy
------------------------------------------------------------------

The three primary, 30-week, PBO-controlled exenatide pivotal trials were conducted in patients with T2DM not achieving glycemic control with MET and/or SFU \[[@R92],[@R95],[@R105]\]. Treatment with ExBID resulted in mean HbA~1c~ reductions ranging from -0.8 to -0.9% (Fig. **[7](#F7){ref-type="fig"}**). For patients treated with ExBID+SFU, when baseline HbA~1c~ was \<9% the mean HbA~1c~ change from baseline was -0.65% and when baseline HbA~1c~ was ≥9% the mean HbA~1c~ change was -1.2% \[[@R92]\]. For patients treated with ExBID+MET+SFU, when baseline HbA~1c~ was (9% the mean HbA~1c~ change from baseline was -0.5% and when baseline HbA~1c~ was ≥9% the mean HbA~1c~ change was .3% \[[@R105]\]. Thus, ExBID reduced HbA~1c~ to a greater extent in patients with higher baseline HbA~1c~, ie, worse glycemic control. The percentage achieving an HbA~1c~≤7% after 30 weeks of ExBID treatment in these pivotal trials ranged from 30% to 46%. These patients also had progressive body weight reductions ranging from -1.6 to -2.8 kg. These improvements in glycemic control and body weight are especially notable, because no specific diet or exercise counseling, nor caloric restriction, were required by the study protocols.

A series of reports followed patients with T2DM originally enrolled in these first three ExBID pivotal trials during open-label extensions with up to 3.5 years of exposure (Tables **[1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**, Fig. **[8](#F8){ref-type="fig"}**) \[[@R87],[@R93],[@R106],[@R110],[@R111]\]. The majority of ExBID-treated patients with T2DM who continued therapy maintained HbA~1c~ reductions in combination with progressive weight loss, with 84% of patients reporting weight loss at Week 104 (2-year evaluable population N=521; 54% completed) \[[@R94]\]. After 3 years of ExBID, patients with T2DM on a background of MET, SFU, or MET+SFU had a mean HbA~1c~ reduction of -1.0%, and 46% achieved an HbA~1c~≤7% \[[@R106]\]. The sustained nature of the glycemic control associated with ExBID therapy may, in part, reflect effects on pancreatic β-cell secretory function, as evidenced by sustained improvements in HOMA-B out to 3 years. Fifty percent lost ≥5% of baseline body weight and 68% had reductions in both HbA~1c~ and weight. This is in contrast to the weight gain associated with many other antidiabetic agents as glycemia improves \[[@R125]\]. After 3.5 years of therapy, 10-mcg ExBID therapy significantly improved a number of cardiovascular risk factors: mean change from baseline was -12% for triglycerides, -6% for LDL-C, -5% for total cholesterol, +24% for HDL-C, -2% for systolic BP, and -4% for diastolic BP \[[@R106]\]. The 25% of ExBID-treated patients who lost the most weight had the greatest improvements in triglycerides, HDL-C, and blood pressure. However, for the entire cohort there were minimal correlations with weight change. These data suggest that ExBID may improve overall cardiometabolic risk factors by mechanisms that are partially dependent on weight loss and partially weight-independent. Data also suggest a role for exenatide in improving cardiometabolic and hepatic biomarkers in patients with T2DM. Elevated serum ALT is a biomarker of hepatic injury, often caused by the nonalcoholic fatty liver disease associated with obesity and T2DM. After 3 years of ExBID, mean ALT in patients with elevated baseline ALT declined progressively (-26%) and 41% had ALT normalization. Although the 25% of patients who lost the most weight had the greatest reduction in ALT, weight change in the entire cohort was only mildly correlated with baseline ALT (r= -0.01) or ALT change r=0.31).

The efficacy of ExBID monotherapy in treatment-naive patients with T2DM was explored in two PBO-controlled clinical trials, one was preliminary \[[@R126]\] and one was phase 3 \[[@R108]\]. In the preliminary study, ExBID monotherapy significantly reduced hyperglycemia and body weight over 28 days of treatment. In the phase 3 study, 24 weeks of ExBID monotherapy significantly reduced mean HbA~1c~ by -0.9%, compared with -0.2% in the PBO group. An HbA~1c~ ≤7% was achieved by 46% with ExBID, compared with only 29% with PBO. Mean daily six-point self-monitored blood glucose concentrations were significantly reduced with ExBID monotherapy compared with PBO (daily mean change -27 mg/dL versus -5 mg/dL, respectively). In addition, β-cell function measured by HOMA-B improved by 28% in the ExBID group compared with 6% in the PBO group.

Insulin Comparator Studies
--------------------------

ExBID has generally demonstrated non-inferiority to insulin glargine and biphasic insulin aspart \[[@R86],[@R88],[@R94],[@R102],[@R109],[@R127]\]. In addition, weight loss was associated with ExBID therapy, compared with weight maintenance or weight gain with insulin therapy. In one study, a strategy of aggressive insulin dose titration reduced HbA~1c~ more with insulin than with ExBID, albeit with greater weight gain in the insulin group \[[@R86]\].

Recently, the data from four ExBID versus insulin comparator studies \[[@R94],[@R102],[@R109],[@R127]\] were pooled (1423 patients) and analyzed \[[@R128]\]. Treatment ranged from 16 to 52 weeks in duration. Overall glycemic control with ExBID (mean HbA~1c~ change -1.2%) was non-inferior to insulin (mean HbA~1c~ change -1.1%) at 6 months, and patients who continued treatment through 52 weeks showed sustained reductions in HbA~1c~ from baseline (ExBID, -1%; insulin, -0.9%). When stratified by HbA~1c~ change from baseline tertiles, ExBID and insulin were associated with comparable reductions in each tertile, with the greatest mean reductions of -1.7% (ExBID) and -1.7% (insulin) observed in the tertile with the highest baseline HbA~1c~ range (9.0% to 12.7%). ExBID was associated with weight loss (mean -2.0 kg) versus weight gain with insulin (mean +1.8 kg) at Week 26; the corresponding values at Week 52 were -3.1 kg vs +1.9 kg. Overall, more ExBID-treated patients (70%) experienced weight loss than did those treated with insulin (21%). For patients with an elevated systolic BP at baseline (≥130 mmHg), ExBID reduced systolic BP to a significantly greater extent than insulin (mean -8.1 vs -3.6 mmHg). The frequency of nocturnal, mild-to-moderate hypoglycemia was lower with ExBID (15%) than with insulin (29%).

Other CVD Effects
-----------------

ExBID effects on BP were analyzed in more depth by pooling data from patients with T2DM treated in six comparator controlled (PBO or insulin) clinical trials of 24 to 52 weeks duration (Fig. **[9](#F9){ref-type="fig"}**) \[[@R129]\]. All patients continued existing antidiabetes, antihypertensive, and dyslipidemia medications. In the pooled analysis, 6 months of ExBID therapy was associated with a significantly greater reduction in systolic BP than was PBO or insulin. Patients with elevated baseline systolic BP (≥130 mmHg) appeared to drive the BP changes observed in the overall population. This subgroup had mean systolic BP reductions with ExBID of -8.3 mmHg versus -4.5 mmHg with PBO; and -8.3 mmHg with ExBID versus -4.2 mmHg with insulin. Although the majority of exenatide-treated subjects lost weight, weight loss was only weakly correlated with systolic BP change (r=0.09), again suggesting exenatide effects were not solely mediated by weight loss.

Clinical trial data from patients with T2DM treated with ExBID or insulin glargine on a background of MET for one year yielded additional insight into the complex metabolic changes associated with exenatide therapy \[[@R130],[@R131]\]. Exenatide treatment reduced total body fat mass and improved the profile of biomarkers for CVD risk compared with insulin glargine. ExBID also significantly reduced post-meal proatherogenic triglycerides, apoB48, VLDL-C, and free fatty acid excursions, as well as the oxidative stress markers MDA and oxLDL-to-LDL ratio compared with insulin glargine. Body weight (-6%), waist circumference (-5%), and total body fat mass (-11%) were all reduced compared with insulin glargine. In addition, there were significant changes in total adiponectin (+12%) and hsCRP (-61%) compared with insulin glargine. In contrast, insulin glargine only significantly reduced endothelin-1 (-7%) compared with ExBID. Notably, the adiponectin and hsCRP changes in the ExBID arm were independent of the changes in total fat mass (adiponectin: r= -0.224; hsCRP: r= -0.023). One year of ExBID also significantly reduced hsCRP in two other comparator-controlled clinical trials \[[@R96],[@R97]\].

Acute exenatide effects on postprandial lipids, remnant lipoproteins, and apolipoproteins in subjects with impaired glucose tolerance or recent onset T2DM were also reported by Schwartz *et al.* \[[@R82]\]. A single exenatide injection prior to a high-fat meal significantly reduced postprandial triglyceride, apoB48, apoCIII, non-esterified fatty acid, and remnant lipoprotein excursions, compared with PBO. Postprandial excursions of total apoB and LDL-C were not changed. These metabolic effects were not affected by the degree of ambient hyperglycemia nor by dyslipidemia treatment with statins.

STUDY ON THE FEASIBILITY OF CONTINUOUS EXENATIDE DOSING
=======================================================

In order to evaluate the feasibility of transitioning from twice daily to once weekly exenatide administration in humans, 12 patients with T2DM treated with diet/exercise or MET received continuous infusions of exenatide or PBO subcutaneously over one-day intervals, delivered via pumps \[[@R131]\]. Exenatide reached therapeutic plasma concentrations (≥50 pg/ml) and significantly reduced plasma glucose during both prandial and fasting states, confirming day-long glycemic control with continuous peptide exposure. There were no serious or severe adverse events, and no cases of hypoglycemia. The most common adverse events with exenatide treatment were mild nausea and/or vomiting.

EXENATIDE ONCE WEEKLY (QW)
==========================

Overview
--------

The formulation of exenatide into a 2-mg once weekly (ExQW) agent differs from ExBID due to encapsulation of the exenatide peptide within poly-(D,L-lactide-co-glycolide) microspheres (Fig. **[10](#F10){ref-type="fig"}**) \[[@R132]\]. After mechanical suspension and subcutaneous injection, ExQW microspheres hydrate in situ and adhere to each other to form an amalgam. A small amount of exenatide (1-2% of the total area under the plasma concentration-time curve) that is loosely bound to the amalgam surface reaches the circulatory system within the first few hours post-injection. Exenatide located in deeper interstices diffuses out more slowly with a T~max~ of approximately 2 weeks. Fully encapsulated exenatide, that is initially inaccessible to diffusion, releases with a T~max~ of approximately 7 weeks as the microspheres hydrolyze and are eliminated as carbon dioxide and water. Plasma exenatide concentrations reach the therapeutic range by 2 weeks post-injection and achieve steady state by 6 to 7 weeks post-injection.

In phase 3 clinical trials, 2-mg ExQW significantly reduced mean HbA~1c~ by -1.3% to -1.9% during controlled treatment periods ranging from 24 to 30 weeks \[[@R113],[@R114],[@R116]-[@R118]\].[1](#FN1){ref-type="fn"} Mean body weight change ranged from -2.3 to -3.7 kg. Further, the proportion of ExQW-treated patients with reductions in both HbA~1c~ and body weight ranged from 70% to 79%.

Initial Clinical Testing
------------------------

The initial phase 2 clinical trial of ExQW evaluated effects in patients with T2DM randomized to ExQW or PBO for 15 weeks on a background of MET or diet/exercise \[[@R133]\]. By Week 2, plasma exenatide concentrations exceeded the minimally effective level (approximately 50 pg/ml) shown to reduce fasting plasma glucose concentrations and remained within the target therapeutic range throughout the remainder of the treatment period. ExQW patients had an HbA~1c~ reduction of -1.7±0.3% compared with an HbA~1c~ increase of 0.4±0.3% in the PBO group. In addition, 86% of patients in the ExQW group achieved an HbA~1c~≤7%, compared with none in the PBO group. Body weight was unchanged in the PBO group, but decreased in the ExQW group by 3.5% (-3.8±1.4 kg). Mild nausea was the most frequent exenatide-associated adverse event (27% versus 15% with PBO). Of note, the incidence of injection site reaction was 7% with ExQW versus 0% with PBO.

Phase 3 Clinical Trials
-----------------------

Phase 3 ExQW clinical development in patients with T2DM is comprised of the DURATION ([D]{.ul}iabetes therapy [U]{.ul}tilization: [R]{.ul}esearching changes in Hb[A]{.ul}~1c~, weight and other factors [T]{.ul}hrough [I]{.ul}ntervention with exenatide [ON]{.ul}ce weekly) program \[[@R134]\]. In the series of DURATION clinical trials completed to date, ExQW has been compared with ExBID (DURATION-1, -5), metformin (DURATION-4), sitagliptin (DURATION-2, -4), pioglitazone (DURATION-2, -4), liraglutide (DURATION-6), and titrated insulin glargine (DURATION-3) on background antidiabetes therapies of diet/exercise, MET alone, or combination OAD therapy (MET, SFU, TZD) (Tables **[1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**) \[[@R86]-[@R120]\].[1](#FN1){ref-type="fn"},[2](#FN2){ref-type="fn"} In controlled treatment periods of the DURATION trials (ranging from 24 to 30 weeks), ExQW significantly reduced mean HbA~1c~ by -1.3% to -2.0% from mean baseline HbA~1c~ values ranging from 8.3% to 8.6%. Mean body weight change ranged from -2.3 to -3.7 kg with ExQW treatment from mean baseline weight values ranging from 88 to 103 kg.

DURATION-1 and -5 directly compared ExQW with ExBID in patients treated with diet/exercise, MET alone, or combination OAD therapy \[[@R114],[@R115]\]. ExQW significantly reduced fasting glucose (Fig. **[11](#F11){ref-type="fig"}**) and glucagon to a greater extent than ExBID. In contrast, ExBID reduced postprandial glucose excursions to a greater extent than did ExQW. During the 30 week controlled portion of DURATION-1, ExQW reduced mean HbA~1c~ by -1.9%. In the open-label extension, patients with T2DM treated with ExQW from baseline had HbA~1c~ reductions of -2.0% at Week 52 \[[@R115]\], -1.7% at Week 104 \[[@R119]\], and -1.6% at Week 156[2](#FN2){ref-type="fn"} on a background of diet/exercise, MET, SFU, TZD, or any 2 OADs. Treatment with ExQW was associated with mean weight reductions of -3.7 kg at Week 30 \[[@R117]\], -4.1 kg at Week 52 \[[@R115]\], -2.6 kg at Week 104 \[[@R119]\], and -2.3 kg at Week 156.[2](#FN2){ref-type="fn"} In DURATION-5, ExQW reduced mean HbA~1c~ by -1.6% and body weight by -2.3 kg on a background of diet/exercise, MET, SFU, TZD, or any combination of the OADs \[[@R114]\].

The second study with long-term data from an open-label extension (DURATION-2) confirmed that glycemic control could be sustained for up to one year with ExQW \[[@R113],[@R120]\]. At the end of the controlled treatment period treatment of 26 weeks, ExQW on a background of MET reduced mean HbA~1c~ by -1.5%, compared with -1.6% at Week 52. The corresponding weight reductions were -2.3 kg and -1.8±0.5 kg, respectively \[[@R114],[@R120]\].

In the DURATION-6 study, ExQW reduced mean HbA~1c~ by -1.3% after 26 weeks of treatment, compared with -1.5% in the liraglutide treatment arm where the liraglutide cohort underwent a forced titration to the maximum approved dose.[1](#FN1){ref-type="fn"} The HbA~1c~ treatment difference was 0.2%, with a 95% confidence interval of 0.08% to 0.34%. Therefore, under the predefined study analysis requiring the upper limit of the HbA~1c~ 95% confidence interval to be \<0.25%, ExQW did not meet the primary endpoint of noninferiority to the maximum daily dose of liraglutide. Mean weight reduction was significantly greater in patients treated with liraglutide (-3.6 kg) than with ExQW (-2.7 kg). Both drugs reduced systolic BP, diastolic BP, and a number of cardiovascular risk factors to a similar extent.

In the only study to evaluate ExQW in drug-naíve patients (DURATION-4), mean HbA~1c~ and body weight changes were -1.5% and -2.0 kg, respectively, after 26 weeks of treatment \[[@R118]\]. However, ExQW is not currently recommended for use as first line therapy in patients failing diet/exercise \[[@R135]\].

In the controlled DURATION trials, the proportion of ExQW-treated patients who had reductions in both HbA~1c~ and body weight ranged from 67% to 79% \[[@R113],[@R114],[@R116]-[@R118]\].[1](#FN1){ref-type="fn"} In DURATION-2 \[[@R112]\], reductions in both HbA~1c~ and body weight occurred in 70% with ExQW, 46% with sitagliptin, and 14% with pioglitazone on a background of MET. In DURATION-3 \[[@R116]\] reductions in both HbA~1c~ and body weight occurred in 79% with ExQW versus 31% with insulin glargine, on a background of MET±SFU. In DURATION-5 \[[@R114]\], reductions in both HbA~1c~ and body weight occurred in 71% with ExQW compared with 51% with ExBID on a background of diet/exercise, MET, SFU, TZD, or a combination of 2 OADs. On the same background therapy, DURATION-1 \[[@R117]\] reported that 73% of ExQW-treated patients had reductions in both HbA~1c~ and body weight, compared with 74% of ExBID-treated patients. In DURATION-4 \[[@R118]\], treatment- naíve patients had reductions in both HbA~1c~ and body weight in 67% with ExQW, 69% with MET, 33% with pioglitazone, and 59% with sitagliptin.

GLP-1 Receptor Agonism Versus Enhancing Endogenous Incretin Levels
------------------------------------------------------------------

As described in the nonclinical sections of this review, the GLP-1 receptor agonist exenatide is resistant to degradation by the DPP-4 enzyme responsible for rapidly metabolizing endogenous GLP-1. An alternative strategy for targeting the GLP-1 signal transduction pathway has been to inhibit DPP-4 activity, which increases the time that endogenous incretins remain active. Exenatide has been directly compared with the DPP-4 inhibitor sitagliptin in patients with T2DM in several clinical trials. In the DURATION-2 trial, 26 weeks of 2-mg ExQW was compared with 100-mg sitagliptin once daily in patients concomitantly treated with MET \[[@R113]\]. Mean HbA~1c~ reductions were significantly greater with ExQW than with sitagliptin (LS mean change from baseline for ExQW: -1.5%, sitagliptin: -0.9%). In addition, ExQW-treated patients lost a mean of -2.3 kg, compared with mean weight loss of -1.5 kg in sitagliptin-treated patients. When patients were later switched from sitagliptin to ExQW for an additional 26 weeks of treatment, mean HbA~1c~was further reduced by -0.3% and mean weight by -1.1 kg \[[@R120]\]. In the DURATION-4 clinical trial, 26 weeks of 2 mg ExQW was compared with 100-mg sitagliptin once daily in treatment-naíve patients \[[@R118]\]. Mean HbA~1c~ reductions were significantly greater with ExQW than with sitagliptin (LS mean change from baseline for ExQW: -1.5%, sitagliptin: -1.2%). LS mean body weight changes were significantly greater with ExQW (-2.0 kg) than with sitagliptin (-0.8 kg). As described in the clinical pharmacology section above, ExBID treatment was also associated with greater effects on glycemic indicators than was sitagliptin \[[@R69],[@R74]\].

EXENATIDE ADVERSE EVENTS IN CLINICAL TRIALS AND ROUTINE CLINICAL USE
====================================================================

Overview
--------

ExBID was approved for human use in 2005 by the U.S. Food and Drug Administration and there is a large clinical trial database of safety events available for analysis \[[@R137]\]. The most common side effects are gastrointestinal in nature, mild, and transient. Nausea is the most prevalent adverse event at drug initiation, and it tends to decrease in frequency with continued exenatide exposure.

Recently, MacConell *et al.* \[[@R137]\] published an integrated analysis of 5594 patients with T2DM from 19 comparator-controlled exenatide BID clinical trials.[3](#FN3){ref-type="fn"} In this report, representing over 1500 patient-years of exposure, the exenatide BID safety profile was compared with the safety profile of a pooled comparator (PBO, insulin aspart, or insulin glargine) cohort treated for 12 to 52 weeks on background therapies of diet/exercise, MET, SFU, TZD, and OAD combinations. Both cohorts had comparable baseline characteristics. For the 3261 exenatide-treated subjects, 44% were female with a mean age of 56 years and a mean BMI of 32 kg/m^2^. Mean baseline HbA~1c~ was 8.3% and mean treatment exposure was 166 days. For the 2333 subjects in the pooled comparator cohort, 46% were female with a mean age of 56 years and a BMI of 32 kg/m^2^. Mean HbA~1c~ was 8.3% and mean treatment exposure time 171 days. No specific safety signals of concern were identified with exenatide use. Both cohorts had comparable rates of serious adverse events, discontinuations due to serious adverse events, and deaths (exenatide: 3.6%, 0.8%, and \<0.1%, respectively; pooled comparator: 3.9%, 0.7%, and \<0.1%, respectively). Consistent with the results from individual clinical trials, transient mild-to-moderate nausea was the most frequent side effect associated with exenatide (36.9% versus 8.3% in the pooled comparator) (Fig. **[12](#F12){ref-type="fig"}**). Overall, gastrointestinal adverse events were more frequently observed with exenatide than with comparator treatment (51% versus 21%, respectively). Gastrointestinal adverse events were also the most common reason for discontinuation of clinical trial participation in the exenatide cohort. Vomiting had a composite frequency of 14% compared with 3% in the pooled comparator group, while diarrhea had a composite frequency of 11% versus 5% in the pooled comparator group. However, nausea and vomiting decreased over time in the exenatide group (independent of dose), with a substantial reduction in incidence rate after 8 weeks of treatment. Of the other most-frequent adverse events (≥5% frequency), only dizziness occurred significantly more frequently with exenatide than with comparator exposure (5% versus 3%, respectively).

In another integrated analysis, MacConell *et al.* published a preliminary report of adverse events from 4,328 patients with T2DM treated in 8 randomized phase 3 ExQW trials. The most frequent adverse events with ExQW were gastroin testinal and injection site-related. These adverse events were generally mild and incidences decreased over time. Gastrointestinal adverse events were lower with ExQW than with ExBID (35% vs 46%, respectively) or another GLP-1 receptor agonist, liraglutide (26% vs 42%, respectively). Hypoglycemia occurred infrequently unless there was concomitant SFU use. The adverse events of pancreatitis, pancreas cancer, thyroid cancer, and renal-related problems were generally similar for ExQW, ExBID, and a pooled comparator group of patients treated in these trials with non-GLP-1 receptor agonists.

An overview of selected adverse effects observed in individual phase 3 exenatide clinical trials are summarized in Table **[3](#T3){ref-type="table"}** \[[@R86]-[@R20]\].[1](#FN1){ref-type="fn"},[2](#FN2){ref-type="fn"} Nausea was the most frequent exenatide side effect, ranging from 12% to 57% upon initiation of 10-mcg exenatide BID (preceded by 4 weeks of 5-mcg ExBID) and 7% to 26% upon first initiation of 2-mg ExQW. Nausea tended to be mild-to-moderate and decreased in frequency with longer duration of exenatide exposure, independent of formulation (BID or QW) \[[@R136]\]. Vomiting had a lower incidence than nausea, ranging from 4% to 22% upon initiation of 10-mcg ExBID and 4% to 11% upon first initiation of 2-mg ExQW. Due to differences in the pharmacokinetic profiles of ExBID and ExQW upon initiation of dosing (rapid achievement of therapeutic concentration of exenatide with ExBID versus 6-7 weeks to achieve final therapeutic concentration of exenatide with ExQW), the lessened incidence and intensity of gastrointestinal side effects with ExQW is not unexpected.

Accidental Overdosing
---------------------

Several reports have described the adverse events associated with exenatide overdosing \[[@R138],[@R139]\]. During one clinical trial, three patients were accidently injected with approximately 100-mcg of exenatide \[[@R138]\]. All three presented with severe nausea and vomiting, and one of them experienced severe hypoglycemia that resolved with intravenous administration of 5% dextrose. All three patients recovered without further sequelae. In another report, Cohen *et al.* \[[@R139]\] discussed the emergency room presentation of a 40-year-old morbidly obese woman with T2DM who self-injected 90-mcg of exenatide in addition to her usual morning medications. The patient presented with dizziness, weakness, nausea, one episode of vomiting, normal vital signs, normal laboratory values, and fasting blood glucose ranging from 84 to 109 mg/dL upon hourly monitoring. Treatment consisted of metoclopramide intravenously. The patient did not become hypoglycemic and fully recovered. In summary, accidental exenatide overdosing was associated with short-term gastrointestinal sequelae and the possibility of an increased hypoglycemia risk. Adverse events due to overdosing have so far been managed successfully with prompt and appropriate medical care.

Hypoglycemia
------------

In the MacConell *et al.* integrated analysis, the overall incidence of hypoglycemia was comparable between groups without SFU use, but between-group differences became apparent when hypoglycemic events were evaluated based on concomitant use of insulin-secretogogue SFU therapy \[[@R136]\]. The incidence rate of mild-to-moderate or major hypoglycemia without concomitant SFU therapy was 3.1% with exenatide and 2.7% with comparators. In contrast, hypoglycemia was more prevalent when exenatide was administered with a SFU (26.5%) than in the pooled comparator cohort (20.7%).

In individual phase 3 exenatide clinical trials major/severe hypoglycemia was rare with 10-mcg ExBID or 2-mg ExQW exposure (Table **[3](#T3){ref-type="table"}**) \[[@R86]-[@R120]\][1](#FN1){ref-type="fn"},[2](#FN2){ref-type="fn"}, ranging from \<1% to 4%. The incidence of all cases of reported hypoglycemia ranged from 0% to 58% upon initiation of 10-mcg ExBID (preceded by 4 weeks of 5-mcg exenatide BID) and 1% to 8% upon first initiation of 2 mg ExQW. Concomitant use of insulin-secretogogue SFU was more often associated with hypoglycemic events than was concomitant MET use. Insulin was usually, but not always, associated with more hypoglycemia than exenatide. In addition, nocturnal hypoglycemia was significantly more frequent in subjects treated with insulin glargine or aspart than with exenatide.

In summary, major/severe hypoglycemia has rarely been observed with ExBID or ExQW use. In the absence of concomitant SFU therapy, the risk of mild-to-moderate hypoglycemia is low. Concomitant SFU increases the risk of hypoglycemic events and SFU discontinuation should be considered when initiating exenatide. ExBID use is associated with a reduced incidence of nocturnal hypoglycemia compared with insulin.

Pancreatitis
------------

In postmarketing data, exenatide administration has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. Of note, acute pancreatitis has been observed in patients treated with exenatide, but it has not been shown that exenatide was causally associated with this adverse event, as will be discussed below. Patient characteristics associated with an increased risk of pancreatitis are overweight/obesity, alcohol use, smoking status, and prior pancreatitis/cholelithiasis/ cholecystectomy \[[@R136]\]. In the MacConell *et al.* \[[@R137]\] integrated analysis discussed above, composite exposure-adjusted incidence rates per 100 patient-years for pancreatitis were not statistically different between the exenatide and pooled comparator groups (0.27 versus 0.18) (Fig. **[13](#F13){ref-type="fig"}**). In addition, occurrence of acute pancreatitis was rare, with a comparable incidence rate of 0.1% in each cohort. In individual phase 3 exenatide clinical trials, pancreatitis was also rare with ExBID or ExQW exposure (Table **[3](#T3){ref-type="table"}**) \[[@R86]-[@R120]\].[1](#FN1){ref-type="fn"},[2](#FN2){ref-type="fn"}

In an analysis using insurance claims from a large U.S. commercial health database, patients with T2DM initiating ExBID were propensity-score-matched with a similar cohort initiating MET or SFU (glyburide) \[[@R140]\]. In this study, exenatide initiators were more likely to be overweight/obese with dyslipidemia and hypertension. Baseline prevalences of gallstone disease (0.8%) and alcohol dependence syndrome (0.1% to 0.2%) were low and comparable across matched-pairs. The estimated absolute risk of hospitalization associated with a primary diagnosis of acute pancreatitis was 0.13% among patients treated with exenatide compared with 0.13% for the matched MET/Gly cohort suggesting that there was no apparent difference in risk. One limitation of this study was that claims for medical services may not meet the strict clinical definition of acute pancreatitis.

In another retrospective analysis of a health insurance claims database, the risk of acute pancreatitis was significantly higher for adults with diabetes than in normoglycemic adults (Cox proportional hazard ratio=2.1) \[[@R141]\]. The incidence of acute pancreatitis in the cohort with diabetes was 5.6 cases per 1,000 subject years. Unlike the previous report, this analysis included patients with evidence of chronic pancreatic disease and estimated the risk of acute pancreatitis after adjusting for medical conditions and medications associated with an increased risk of acute pancreatitis. Among patients with T2DM, the risk of acute pancreatitis was comparable in the exenatide-treated cohort and the T2DM control cohort (Cox proportional hazard ratio=1.0).

A more recent evaluation of patients with diabetes (types 1 or 2), and without prior insurance claims for pancreatic disease, found no increased risk of emergency room treatment or hospitalization associated with acute pancreatitis in patients currently taking exenatide compared with a matched cohort on other antidiabetes drugs (propensity score adjusted risk ratio=0.5) \[[@R142]\]. Past exposure to exenatide, defined as more than 62 days after exhaustion of a patient\'s drug supply, was associated with an increased risk (risk ratio 2.8). However, after adjustment for all chart-derived patient characteristics associated with an increased risk of pancreatitis (overweight/obese, alcohol use, smoking status, and prior pancreatitis/ cholelithiasis/ cholecystectomy) and contemporaneous claim-identified covariates, the past-time estimate was consistent with no increased risk for acute pancreatitis with past exenatide exposure relative to past exposure to other antidiabetes drugs (odds ratio 1.1).

Based on the medical literature (range 1950 to January 2010), FDA website (range 2005 to August 2008), and Amylin Pharmaceuticals database, Anderson and Trujillo \[[@R143]\] published a review of pancreatitis reports associated with ExBID use. The pancreatitis incident rate during clinical development was 1.8 per 1000 subject years for exenatide, compared with 2.6 per 1000 subject years for PBO and 0.9 per 1000 subject years for insulin. Among the FDA-reviewed post-marketing cases of pancreatitis, all 6 patients with hemorrhagic or necrotizing pancreatitis required hospitalization and 2 died. For the 30 other cases of pancreatitis, 19 patients were female (63%) with a median age of 60 years and a time-to-onset of symptoms ranging from 4 to 300 days after exenatide initiation (median 34 days post-exenatide). In 22 cases of pancreatitis the patients improved after exenatide discontinuation and in 21 cases of pancreatitis the patients required hospitalization. Of note, 27 of the 30 patients had at least one other risk factor for acute pancreatitis.

Elashoff *et al.* \[[@R144]\] used the U.S. Food and Drug Administration (FDA) adverse event reporting system (AERS) database to analyze putative associations between exenatide and cases of pancreatitis, pancreatic cancer, thyroid tumors, and all cancers. As cautioned by the authors, the FDA AERS database depends on spontaneous reporting and is thus, subject to reporting biases. The control antidiabetes drugs were rosiglitazone (TZD), nateglinide, repaglinide, and glipizide (SFU). Back pain, urinary tract infection, chest pain, cough, and syncope were prospectively defined as the control adverse events. By design, no comparable analyses were performed to assess the rates of pancreatitis and cancer associated with the control drugs. The fundamental assumptions in the analysis were no association between the control drugs and control events, or between exenatide and control events. The period covered was 2004 through the third quarter of 2009.Within this framework, the authors found an increased risk of pancreatitis and pancreatic cancer associated with exenatide compared with the control drugs (odds ratio 10.68). When the subset of pancreatitis reports in 2006 and prior (before the first cautionary letter from the FDA in 2007) were analyzed, the odds ratio for exenatide, compared with control drugs, was 2.57 for pancreatitis, 2.95 for pancreatic cancer, 4.73 for thyroid cancer, and 1.08 for all other cancers. Given the potentially serious safety concerns raised by Elashoff *et al.* \[[@R144]\], the European Association for the Study of Diabetes (EASD) evaluated the report in detail \[[@R145]\]. The EASD acknowledged the importance of continual safety monitoring of diabetes therapeutics, but concluded there was no definitive evidence pointing to an increased cancer risk with incretin-based medications. The EASD reiterated the incompleteness and bias associated with spontaneous adverse events reporting systems such as the FDA database. Also, given the analysis period covered by Elashoff *et al.* \[[@R144]\], there was a significant amount of time before exenatide market introduction when only events with control therapy were collected, possibly introducing further bias. In addition, reported events are not evaluated for their adherence to accepted diagnostic standards. EASD stated that the only robust way of measuring comparative risk is within randomized control trials.

In summary, the incidence of acute pancreatitis is rare in patients with T2DM, whether or not they are being treated with exenatide or other diabetes drugs. However, additional monitoring to compile long-term exposure data is warranted, with randomized, controlled clinical trials as the recommended methodology.

All patients treated with exenatide should be monitored for the signs and symptoms of pancreatitis, including persistent severe abdominal pain, possibly radiating to the back, which may or may not be accompanied by vomiting \[[@R135],[@R146]\]. If pancreatitis is suspected, exenatide should be discontinued. If pancreatitis is confirmed, exenatide should not be restarted. Exenatide should not be used in patients with a history of pancreatitis.

Neoplasias
----------

In both genders of rats, exenatide caused a dose-related and treatment-duration dependent increase in the incidence of thyroid C-cell tumors at clinically relevant exposures compared to controls \[[@R136],[@R146]\]. A significant increase in malignant thyroid C-cell carcinomas was observed in female rats receiving exenatide at 25-times clinical exposure compared to controls and higher incidences were noted in males above controls in all treated groups at ≥2-times clinical exposure. Other GLP-1 receptor agonists have also been shown to induce thyroid C-cell adenomas and carcinomas in male and female mice and rats at clinically relevant exposures \[[@R144]\]. It is unknown whether exenatide will cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of exenatide-induced rodent thyroid C-cell tumors could not be determined by clinical or nonclinical studies..

As to the topic of \'thyroid cancer\' in humans raised by the Elashoff *et al.* analysis \[[@R144]\], the EASD \[[@R145]\] stated that there are different categories of thyroid cancer, with different molecular characteristics and etiologies. The only form possibly mechanistically-related to incretin-based antidiabetic drugs that could potentially be influenced by therapies leading to enhanced stimulation of the GLP-1R is a cascade leading from C-cell hyperplasia to C-cell adenoma to medullary thyroid carcinoma. Medullary thyroid carcinoma is one of the rarer forms of thyroid tumors and it seems counter-intuitive that a change in the incidence in medullary thyroid carcinoma would change the overall incidence of thyroid carcinomas. A similar viewpoint was expressed by Spranger *et al.* \[[@R147]\] for the Drug Commission of the German Medical Association. According to the authors, the time between tumor induction, tumor development, and metastasis/clinical diagnosis generally extends more than 10 years. By contrast, spontaneous adverse drug reactions in the German national database consistently found the time between initial exenatide exposure and tumor detection to be much shorter (2 to 33 months). Thus, the authors concluded that a role for exenatide in tumor induction was doubtful.

In the MacConell *et al.* integrated analysis \[[@R137]\], a small difference was observed between the exenatide BID and pooled comparator groups in the incidence of thyroid tumors (0.3% versus 0.0%, respectively).

In summary, a causal relationship between the development of neoplasias and treatment with exenatide or other diabetes drugs has not been proven in patients with T2DM. However, additional monitoring to compile long-term exposure data is warranted, with randomized, controlled clinical trials as the recommended methodology. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not be treated with exenatide \[[@R136],[@R146]\].

Exenatide Use in Renal Disease
------------------------------

Exenatide is primarily metabolized and cleared in the kidney \[[@R148]\], and exenatide pharmacokinetics are significantly altered (i.e., reduced clearance rate, increased half-life) in nondiabetic adults with end-stage renal disease \[[@R149]\]. In addition, ExBID may induce nausea and vomiting, resulting in transient hypovolemia possibly leading to worsened renal function. Therefore, it is prudent to proceed conservatively in patients with moderate renal impairment (creatinine clearance 30-50 mL/min) and to avoid exenatide use completely in patients with end-stage renal disease or severe renal impairment (creatinine clearance \<30 mL/min) \[[@R136],[@R146]\].

In the MacConell *et al.* \[[@R137]\] integrated ExBID analysis, there was no between-cohort difference in exposure-adjusted incidence rates per 100 patient-years for renal impairment/failure (1.6 for each cohort).

In summary, caution should be used when initiating or escalating exenatide therapy in patients with T2DM and moderate renal impairment. Exenatide should not be used in patients with end-stage renal disease or severe renal impairment (creatinine clearance \<30 ml/min), and should be used with caution in patients with renal transplantation.

Cardiovascular Effects
----------------------

Ratner *et al.* \[[@R150]\] reported a retrospective analysis of major adverse cardiac events (MACE) in 3945 subjects from 12 randomized exenatide BID clinical trials; 8 PBO-controlled and 4 active comparator-controlled (Fig. **[14](#F14){ref-type="fig"}**). For this evaluation, MACE included cardiovascular mortality, stroke, myocardial infarction, acute coronary syndrome, and revascularization procedures. Of note, in the clinical trials included in this analysis, patients were excluded from study participation if they had a significant history of cardiac disease at screening, or active cardiac disease within 1 year prior to screening. In this population, MACE occurred infrequently. At baseline, mean HbA~1c~ was 8.3% to 8.4%, mean BMI was 31.3 to 31.5 kg/m^2^, mean systolic BP was 131 to 132 mmHg, and mean diastolic BP was 79 mmHg. There were 4 fatal CV events, 2 in each treatment cohort. The exenatide cohort had an exposure-adjusted incidence rate per 100 patient-years of 1.9, versus 2.3 for the comparator cohort. In a weighted Kaplan-Meier plot a significantly higher percentage of the exenatide cohort than the pooled comparator cohort were free of a primary MACE event over 1 year.

The effects of 10-mcg ExBID on heart rate was prospectively evaluated in a small, 12-week, PBO-controlled pilot study \[[@R101]\]. Overweight patients with T2DM with stage-1 hypertension and treated with MET, TZD, or MET+TZD for their hyperglycemia had no change from baseline in heart rate in either treatment arm. Exenatide was not associated with a significant change from baseline in mean 24-hour, daytime, or nighttime heart rate within or between groups.

Overall, available clinical trial data indicate that treatment with exenatide BID does not increase cardiovascular risk in patients with T2DM.

Anti-exenatide Antibody Formation and Injection-site Reactions
--------------------------------------------------------------

Xenogenic peptide therapies, such as exenatide, often stimulate an antibody response and the clinical impact of this immune response can range from none to life threatening \[[@R151]\]. Antibody rates for all xenogenic peptide therapies can vary from less than 1% to over 70%. However, not all antibodies are neutralizing, nor do all antibody responses result in attenuation of drug efficacy, altered pharmacokinetics/pharmacodynamics, or changes in drug clearance. In the majority of cases, the antibody response to xenogenic peptides is benign, with minimal clinical impact.

In an integrated analysis of patients with T2DM exposed to ExBID in controlled clinical trials, 35% of all patients were antibody-positive at endpoint (12 to 52 weeks of treatment); 33% of all patients had low antibody titers (≤125) \[[@R152]\]. For patients exposed to ExQW in clinical trials, 57% were antibody-positive at the endpoints of the controlled periods (24 to 30 weeks); but most (88%) had low antibody titers. In ExQW patients, 22% with detectable antibodies had potentially immune-related treatment-related adverse events, versus 12% in antibody-negative subjects and 10% in the pooled comparator control group. Injection-site erythema or pruritus was reported in 13.6% of antibody-positive patients treated with ExQW, compared with 3.1% of antibody-negative patients and 2.9% of comparator control patients. No anaphylactic reactions occurred with either exenatide formulation.

In summary, anti-exenatide antibody responses are common in patients treated with ExBID or ExQW. However, the incidence of all immune-related adverse events is low. Injection-site erythema or pruritus was observed in patients treated with ExQW, but no anaphylactic reactions have occurred with either exenatide formulation.

Special Populations
-------------------

One small PBO-controlled study directly compared exenatide safety in elderly patients with T2DM ≥75 years of age (n=15) with middle-aged patients with T2DM ≥45 to ≤65 years of age (n=15) \[[@R153]\]. At baseline, the elderly cohort had mild or moderate renal impairment, while the middle-aged cohort had normal renal function. Treatment was administered over three consecutive days. Nausea and vomiting with ExBID were more prevalent in the elderly cohort (nausea: 6 patients versus control 3 patients; vomiting: 3 patients versus 1 control patient). All other adverse events were similar in both groups, and none were severe in intensity. There were no reports of hypoglycemia.

FUTURE DIRECTIONS
=================

A once monthly formulation of exenatide (ExQM) is currently undergoing clinical evaluation.[4](#FN4){ref-type="fn"} This formulation uses the extended-release microspheres of ExQW with a triglyceride-based diluent to enable delivery of higher exenatide doses less frequently. A 20-week, randomized, open-label, controlled trial was conducted in 121 patients with T2DM treated with diet/exercise, MET, TZD (pioglitazone) or MET+TZD. Three ExQM doses (5, 8, or 11 mg) administered 5 times as directed were compared with ExQW administered 20 times. Sustained plasma exenatide concentrations were achieved with all ExQM doses, although greater peak-to-trough variability in exenatide pharmacokinetic profiles was observed with ExQM than with ExQW. However, the mean trough concentrations remained within the therapeutic range with all ExQM doses. The 8- and 11-mg ExQM doses achieved plasma exenatide concentrations similar to those of ExQW. All three ExQM doses reduced mean HbA~1c~ by -1.3% to -1.5%, compared with an ExQW mean HbA~1c~ reduction of -1.5%. Seventy percent of patients achieved an HbA~1c~(7% on the 11-mg ExQM dose versus 48% with ExQW. Patients dosed with 11-mg ExQM lost -1.1 kg of body weight, compared with -1.4 kg in the ExQW group. The overall safety profile was comparable between ExQM and ExQW. No hypoglycemia was observed. Based on these preliminary results, more extensive clinical trials are planned.

An ongoing, prospective morbidity and mortality outcomes study (EXSCEL) is expected to further elucidate the potential cardiovascular implications of ExQW in patients with T2DM[5](#FN5){ref-type="fn"}. The primary outcome measure is the time to first cardiovascular event in a combined endpoint consisting of cardiovascular-related death, nonfatal myocardial infarction, or nonfatal stroke. Secondary endpoints include the time to all-cause mortality, time to first cardiovascular event, time to hospitalization for acute coronary syndrome, and time to hospitalization for heart failure. Recruitment for this trial is ongoing.

SUMMARY AND CONCLUSION
======================

This review presents an overview of the evolution of exenatide as a treatment for T2DM beginning with the realization of the importance of the \'incretin effect\', through seminal preclinical discoveries, clinical pharmacology investigations, and phase 3 clinical trials. Currently, a twice daily exenatide formulation is approved for use in patients with T2DM in the U.S., E.U., Japan, and other countries. More recently, a once weekly exenatide formulation was approved for use in the U.S. and EU. In addition, a once-monthly exenatide formulation is undergoing clinical testing. In patients with T2DM, glycemic control is not always achieved, and some therapeutic interventions cause hypoglycemia and weight gain, or possibly exacerbate the risk of CVD. In clinical trials, exenatide treatment has addressed these unmet medical needs with T2DM patients experiencing improved glycemia, weight loss, and a low frequency of hypoglycemia in the absence of concurrent SFU (insulin secretogogue) use. The effects of exenatide have been shown to be mediated through enhanced glucose-dependent insulin secretion, suppressed inappropriately elevated glucagon secretion, slowed gastric emptying, and enhanced satiety.

In controlled phase 3 clinical trials ranging from 12 to 52 weeks in duration, 10-mcg ExBID reduced mean HbA~1c~ by -0.8% to -1.7%, accompanied by mean weight loss ranging from -1.2 kg to -8.0 kg, plus improvements in a broad range of cardiometabolic risk factors. Efficacy has been demonstrated as monotherapy and in various combinations with metformin (MET), sulfonylureas (SFU), thiazolidinediones (TZD), and insulins. During phase 3 clinical evaluation of a once weekly exenatide (ExQW) formulation in patients with T2DM in controlled trials ranging from 24 to 30 weeks, 2 mg ExQW reduced mean HbA~1c~ by -1.3% to -1.9%, accompanied by mean body weight reductions ranging from -2.3 to -3.7 kg; with 70% to 79% having reductions in both HbA~1c~ and weight. In the DURATION-1 study extension, ExQW was associated with mean HbA~1c~ reductions of -2.0% at Year 1 and -1.7% at Year 2, on a background of diet/exercise, MET, SFU, TZD, or 2 oral antidiabetes drugs; the corresponding mean weight reductions were -4.1 kg and -2.6 kg.

The most common side effects are gastrointestinal in nature, mild, and transient. Nausea is the most prevalent adverse event and tends to decrease in frequency with continued exenatide exposure. The incidence of hypoglycemia without concomitant SFU therapy is generally low; hypoglycemia incidence increases when exenatide is used in conjunction with a SFU. Rare cases of pancreatitis have been reported, typically at the same incidence rate as for other diabetes drugs. A causal relationship between the development of neoplasias and treatment with exenatide or other diabetes drugs has not been proven in patients with T2DM. However, additional monitoring to compile long-term exposure data is warranted, with randomized, controlled clinical trials as the recommended methodology. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not be treated with exenatide. No detrimental cardiovascular effects have been identified. Most patients develop low titer anti-exenatice antibodies with little or no physiological consequences. No anaphylaxis has been reported with exenatide use. Thus, by building upon early observations of anti-hyperglycemic actions of GLP-1 and Gila monster exendin-4, exenatide (synthetic exendin-4) has been successfully developed into a first-in-class diabetes therapeutic.
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:    =  background

BG
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:    =  European Association for the Study of Diabetes
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FDA
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HbA~1c~
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Hypo
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ILM
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KO
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:    =  lunch
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:    =  liraglutide
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MET

:    =  metformin
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:    =  once daily

QM
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ΔRx
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SFU
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See Table **[1](#T1){ref-type="table"}**

![Timeline for the evolution of exenatide (synthetic exendin-4) as a diabetes therapeutic. (Created from references \[[@R7],[@R12],[@R13],[@R16]-[@R24],[@R32]-[@R34],[@R39],[@R40]-[@R57],[@R60]-[@R66],[@R69]-[@R121],[@R126],[@R127],[@R130]-[@R132],[@R135],[@R137],[@R145]\]).](CDR-9-161_F1){#F1}

![**(A)** Representative diagram of the incretin effect in healthy volunteers after administration of a 50 g oral glucose bolus or an equivalent isoglycemic intravenous glucose infusion. The increasing plasma glucose concentrations (*left panel*) results in an increase of plasma insulin concentrations (*right panel*). However, the route of glucose administration (oral or intravenous) determines the extent of the resulting β-cell response. This difference (incretin effect) prompted investigations into the role of incretins, factors secreted from the intestinal tract upon food ingestion that enhance the insulin secretion. (Adapted from sub in reference \[[@R8]\]). (**B)**Illustration depicting the normal physiological actions of GLP-1. GLP-1 stimulates replenishment of insulin stores via stimulation of proinsulin gene expression in β-cells; promotes the differentiation of progenitors derived from pancreatic islets into functioning β-cells; reduces apoptosis in pancreatic islets; and reduces ambient glucose concentrations via inhibition of glucagon secretion from pancreatic α-cells. GLP-1 also decelerates the rate of gastric emptying; reduces food intake and body weight; and promotes satiety. In addition, GLP-1 acts on the heart by improving myocardial function and cardiac output. (Adpated from references \[[@R154]\] and \[[@R155]\]).](CDR-9-161_F2){#F2}

![Treatment effects of continuous subcutaneous GLP1 infusion for 6 weeks in patients with T2DM. **(A, B)** Plasma glucose concentrations. GLP-1 significantly reduced fasting plasma glucose compared with saline or baseline.**(C, D)** Plasma C-peptide concentrations during a hyperglycemic clamp. The insert shows the first-phase secretory response (incremental 0-10 min) for patients receiving GLP-1. GLP-1 significantly stimulated the β-cell secretory response compared with saline or baseline. Mean±SEM. (Reprinted with permission from reference \[**[@R35]**\].)](CDR-9-161_F3){#F3}

![Amino acid sequence comparison for exendin-4 and GLP-1. (Adapted from references \[[@R13],[@R40],[@R41]\]).](CDR-9-161_F4){#F4}

![Exenatide treatment for 5 days restored a more normal glycemic profile in patients with T2DM. Fasting plasma glucose (**A**), serum insulin (**B**), and (C) glucagon concentrations during the 8 hours following a single dose of placebo (n=11) or 0.1 µg/kg exenatide administered at t = 0 (n=12). Mean±SEM. (**D, E, F**) Postprandial plasma glucose (**D**), insulin (**E**), and glucagon (**F**) concentrations following a single dose of placebo or 0.1 µg/kg exenatide at t=0 followed by a standardized meal. Postprandial glucose: Placebo n=20; Exenatide n=20. Post-prandial insulin: Placebo n=16; exenatide n=16. Postprandial glucagon: Placebo n=20; Exenatide n=20. **(**Adapted from reference \[**[@R61]**\]).](CDR-9-161_F5){#F5}

![Insulin secretory response and glucagon counterregulatory hormone response. Basal period: \~30 to 0 min. Infusion of exenatide or placebo commenced at 0 min. Glycemic steps: 0-120 min, euglycemia with plasma glucose at \~5.0 mmol/L; 120--180 min, hypoglycemia with plasma glucose at \~4.0 mmol/L; 180-240 min, hypoglycemia with plasma glucose at \~3.2 mmol/L ending in nadir of \~2.8 mmol/L; 270-360 min, recovery phase. Open circles, placebo treatment arm; Filled circles, exenatide treatment arm. Data are mean±SEM. N=11 per treatment arm. \**P*\<0.05, exenatide versus placebo during the steady-state of the indicated glycemic interval. (Reprinted with permission from reference \[[@R82]\]).](CDR-9-161_F6){#F6}

![ExBID treatment reduced HbA~1c~ and body weight in patients with T2DM in the three pivotal phase 3 clinical trials on differing oral antidiabetes drug backgrounds. At Week 30, significant HbA~1c~ and weight reductions were observed in all ExBID groups compared with placebo (p\<0.05). LS mean±SEM. (Adapted from references \[[@R92],[@R95],[@R105]\]).](CDR-9-161_F7){#F7}

![Long-term efficacy of ExBID on HbA~1c~ (**A**) and body weight (**B**). (**C**) Individual patient data showing that the majority of exenatide-treated patients (84%) lost weight after 3-years of ExBID therapy. (**D**) Individual patient data showing that the majority of exenatide-treated patients (68%) both lost weight and had reduced HbA~1c~ after 3-years of ExBID therapy. N=217 (Reprinted with permission from reference \[**[@R106]**\]).](CDR-9-161_F8){#F8}

![Pooled analysis of systolic blood pressure data from six ExBID clinical trials including 2,171 patients with T2DM. (**A**) Systolic blood pressure change from baseline in patients treated with ExBID or placebo for 6 months. Mean+SEM. (**B**) Systolic blood pressure change from baseline in patients treated with ExBID or insulin for 6 months. Mean+SEM. (Reprinted with permission from reference \[**[@R129]**\]).](CDR-9-161_F9){#F9}

![ExQW mechanism of drug release from poly-(D,L-lactide-co-glycolide) microspheres. (Reprinted with permission from reference \[**[@R133]**\]).](CDR-9-161_F10){#F10}

![**(A-D)**Comparison of treatment effects for ExQW versus ExBID over 24 weeks in the duration-5 phase 3 clinical trial in treatment-naíve patients with T2DM. (**A**) HbA~1c~ change from baseline. LS mean±SEM. (**B**) Proportion of subjects achieving HbA~1c~ targets at study end. \*p\<0.0001. (**C**) Fasting plasma glucose change from baseline. LS mean±SEM. (**D**) Body weight change from baseline. LS mean±SEM. ITT population: ExQW n=129; ExBID n=123. (A-D adapted from reference \[[@R114]\]). (**E**) Comparison of postprandial glucose effects after a normal meal in patients treated with ExQW or ExBID at baseline and at Week 14 in the duration-1 phase 3 clinical trial in patients with T2DM. ExQW n=27; ExBID n=24. (Adapted from reference \[[@R117]\]) (**F**) HbA~1c~ change from baseline in the 2-year extension of the duration-1 clinical trial. 2-year completer population: ExQW n=216. LS mean±SEM. (Adapted from reference \[[@R119]\]).](CDR-9-161_F11){#F11}

![Incidence, recurrence, and duration of nausea and vomiting with ExBID (4-week lead-in period with 5 mcg BID followed by a dose increase to 10 mcg BID for the duration of the trial). ExBID n=2558. Placebo n=1325. Insulin n=1008. (**A**) Occurrence and recurrence of nausea over time (grouped into 4-week intervals). (**B**) Occurrence and recurrence of vomiting over time (N=2558). Each event is attributed to a defined period according to the event onset date, and recurrence of nausea/vomiting is defined as an event with onset during the defined period and previous period. Percentages are based on number of subjects who remained in the trial during the defined period. (**C**) Duration of nausea. (**D**) Duration of vomiting. The duration of the nausea/vomiting event is calculated as the resolution date (or the last participation date if an event is ongoing at the time of study termination) minus the event onset date plus 1. (Reprinted with permission from reference \[**[@R137]**\]).](CDR-9-161_F12){#F12}

![Adverse events of interest. Exposure-adjusted incidence rate (EAIR) and risk difference of thyroid neoplasm, pancreatitis, renal impairment, and major adverse cardiac events (MACE). ExBID n=3261. Pooled comparator n=2333. MACE n=2316 and 1629, respectively. Thyroid neoplasm includes benign neoplasm of thyroid gland and malignant thyroid neoplasm. Pancreatitis includes acute pancreatitis and chronic pancreatitis. Renal impairment includes renal failure. MACE includes stroke, myocardial infarction, cardiac mortality, acute coronary syndrome, and revascularization procedures. ^a^95% confidence interval for the risk difference (RD, ExBID incidence rate \[%\] minus pooled comparator incidence rate \[%\]). ^b^MACE analysis: risk ratio (RR) and 95% confidence interval for the RR. PY=patient-years. (Reprinted with permission from reference \[[@R137]\]).](CDR-9-161_F13){#F13}

![(**A**) Relative risk of primary MACE and secondary cardiovascular endpoints with ExBID relative to pooled comparators. (**B**) Weighted Kaplan-Meier plot for patients without a primary MACE event by treatment in controlled ExBID studies. (Reprinted with permission from reference \[[@R150]\].](CDR-9-161_F14){#F14}

###### 

Overview of Exenatide Phase 3 Clinical Trial Designs.

  Study Citation                   Study Dur (wk)   Double Blind?   Multi-National? (\#countries)   Analysis Pop         Mean Calc       NCT\#[a](#T1FN1){ref-type="fn"}
  -------------------------------- ---------------- --------------- ------------------------------- -------------------- --------------- ---------------------------------
  **Exenatide BID**                                                                                                                      
  Bergenstal 2009 \[[@R86]\]       24               No              No (US)                         ITT & per protocol   Mean            00097877
  Blonde 2006 \[[@R87]\]           82               No              No (US)                         ITT & completers     Mean            00111540
  Bunck 2009 \[[@R88]\]            52               No              Yes (3)                         ITT & evaluable      Mean            00097500
  Bunck 2011 \[[@R89]\]            168              No              Yes (3)                         ITT & evaluable      Mean            00097500
  Buse 2011 \[[@R90]\]             30               Yes             Yes (5)                         ITT                  LS Mean         00765817
  Buse 2009 \[[@R91]\]             26               No              Yes (15)                        ITT & per protocol   LS Mean         00518882
  Buse 2004 \[[@R92]\]             30               Yes             No (US)                         ITT & evaluable      Mean            00039026
  Buse 2007 \[[@R93]\]             104              No              No (US)                         ITT & completers     Mean            00111540
  Davies 2009 \[[@R94]\]           26               No              No (UK)                         ITT                  LS Mean         00360334
  DeFronzo 2005 \[[@R95]\]         30               Yes             No (US)                         ITT & evaluable      Mean            00039013
  Derosa 2010 \[[@R96]\]           52               No              No (Italy)                      ITT                  Mean            NA
  Derosa 2011 \[[@R97]\]           52               No              No (Italy)                      ITT                  Mean            NA
  Forti 2008 \[[@R98]\]            12               No              Yes (2)                         Per protocol         LS Mean         00359879
  Gallwitz 2011 \[[@R99]\]         26               No              No (Germany)                    ITT                  LS Mean         00434954
  Gao 2009 \[[@R100]\]             16               Yes             Yes (4)                         ITT & per protocol   LS Mean         00324363
  Gill 2010 \[[@R101]\]            12               Yes             Yes (2)                         ITT & per protocol   LS Mean         00516074
  Heine 2005 \[[@R102]\]           26               No              Yes (13)                        ITT & per protocol   LS Mean         00082381
  Kadowaki 2009 \[[@R103]\]        12               Yes             No (Japan)                      ITT                  Mean            00382239
  Kadowaki 2011 \[[@R104]\]        24               Yes             No (Japan)                      ITT                  LS Mean         00577824
  Kendall 2005 \[[@R105]\]         30               Yes             No (US)                         ITT & evaluable      Mean            00035984
  Klonoff 2008 \[[@R106]\]         156 / 182        No              No (US)                         ITT & completers     Mean            00111540
  Liukus 2010 \[[@R107]\]          26               Yes             Yes (5)                         ITT                  LS Mean         00603239
  Moretto 2008 \[[@R108]\]         24               Yes             Yes (4)                         ITT                  LS Mean         00381342
  Nauck 2007 \[[@R109]\]           52               No              Yes (13)                        ITT & per protocol   Mean            00082407
  Ratner 2006 \[[@R110]\]          82               No              No (US)                         ITT & completers     Mean            00111540
  Riddle 2006 \[[@R111]\]          82               No              No (US)                         ITT & completers     Mean            00111540
  Zinman 2007 \[[@R112]\]          16               Yes             Yes (3)                         ITT & per protocol   LS Mean         00099320
  **Exenatide QW**                                                                                                                       
  Bergenstal 2010 \[[@R113]\]      26               Yes             Yes (3)                         ITT & evaluable      LS Mean         00637273
  Blevins 2011 \[[@R114]\]         24               No              No (US)                         ITT & evaluable      LS Mean         00877890
  Buse 2010 \[[@R115]\]            52               No              Yes (2)                         ITT & evaluable      LS & Geo Mean   00308139
  Buse 2011**^1^**                 26               No              Yes (21)                        ITT                  LS Mean         01029886
  Diamant 2010 \[[@R116]\]         26               No              Yes (15)                        ITT                  LS Mean         00641056
  Drucker 2008 \[[@R117]\]         30               No              Yes (2)                         ITT & evaluable      LS & Geo Mean   00308139
  MacConell 2011**^2^**            156              No              Yes (2)                         Completers           LS & Geo Mean   00308139
  Russell-Jones 2012 \[[@R118]\]   26               Yes             Yes (22)                        ITT                  LS Mean         00676338
  Taylor 2011 \[[@R119]\]          104              No              Yes (2)                         ITT & Completers     LS Mean         00308139
  Wysham 2011 \[[@R120]\]          52               No              Yes (3)                         Evaluable            LS Mean         00637273

Additional information on these trials is available at [clinicaltrials.gov](clinicaltrials.gov)

Abbreviations: BID, twice daily; Dur, duration; Geo, geometric; ITT, intent-to-treat; LS, least squares; NA, not applicable; NCT, national clinical trial database; NI, non-inferiority; Pop, population; QW, once weekly; **Δ**Rx, change or different diabetes medication prior to randomization; S, superiority.

###### 

Overview of Exenatide Phase 3 Clinical Studies.[a](#T2FN3){ref-type="table-fn"}

  Study Citation                           Ther Studied    BG Ther                          DO (%)   ITT N   F (%)   White (%)    T2DM Dur (y) ±SD                             BL HbA~1c~ (%) ±SD                      ΔHbA~1c~ (%) ±SE                              Achieved HbA~1c~ ≤7% or \<7% (%)        BL BMI (kg/m^2^) ±SD                         BL Wt (kg) ±SD   ΔWt (kg) ±SE
  ---------------------------------------- --------------- -------------------------------- -------- ------- ------- ------------ -------------------------------------------- --------------------------------------- --------------------------------------------- --------------------------------------- -------------------------------------------- ---------------- --------------------------------------------
  **Exenatide BID**                                                                                                                                                                                                                                                                                                                                                        
  Bergenstal 2009 \[[@R86]\]               ExBID           MET + SFU                        29.8     124     51.6    63.7         9±6                                          10.2±1.5                                -1.75                                         20                                      34±7                                         96.6±24          -1.9
  Aspart QD                                16.1            124                              51.6     67.7    8±6     10.1±1.8     -2.34                                        26                                      34±7                                          96.9±25                                 2.8                                                           
  Aspart BID                               19.4            124                              52.4     59.7    10±6    10.3±1.9     -2.76                                        37                                      34±7                                          93.8±24                                 4.1                                                           
  Blonde 2006 \[[@R87]\]                   ExBID           MET +/or SFU                     43.0     551     39      74           7±6                                          8.4±1.0                                 -1.1±0.1                                      48                                      34±6                                         98±20            -4.4±0.3
  Bunck 2009 \[[@R88]\]                    ExBID           MET                              16.7     36      36.1    100          6±1                                          7.6±0.1                                 -0.8±0.1                                      NG                                      31±1                                         90.6±2.1         -3.6 ±0.6[\*](#T2FN2){ref-type="table-fn"}
  Glarg                                    9.1             33                               33.3     97      4±1     7.4±0.1      -0.7±0.2                                     NG                                      30±1                                          92.4±2.4                                1.0±0.8                                                       
  Bunck 2011 \[[@R89]\]                    ExBID           MET                              44.4     36      36.1    100          6±1                                          7.6±0.1                                 -1.0                                          NG                                      31±1                                         90.6±2.1         -5.7 ±1.3[\*](#T2FN2){ref-type="table-fn"}
  Glarg                                    48.5            33                               33.3     97      4±1     7.4±0.1      -0.5                                         NG                                      30±1                                          92.4±2.4                                2.1±1.3                                                       
  Buse 2011 \[[@R90]\]                     ExBID           Glarg ±MET and/or TZD            19       137     49      75           12±7                                         8.32± 0.85                              -1.74 ±0.1[\*](#T2FN2){ref-type="table-fn"}   60[\*](#T2FN2){ref-type="table-fn"}     34±6                                         95.4±20.4        -1.8 ±0.3[\*](#T2FN2){ref-type="table-fn"}
  PBO                                      18              122                              36       80      12±7    8.50± 0.96   -1.04 ±0.1                                   35                                      33±6                                          93.4±21.2                               1.0±0.3                                                       
  Buse 2009 \[[@R91]\]                     ExBID           MET ± SFU                        19.5     231     45      91           8±6                                          8.1±1.0                                 -0.8±0.1                                      43                                      33±6                                         93.0±19.5        -2.9±0.3
  LIRA                                     14.2            233                              51       93      9±6     8.2±1.0      -1.1±0.1                                     54                                      33±6                                          93.1±20.1                               -3.2±0.3                                                      
  Buse 2004 \[[@R92]\]                     ExBID           SFU                              29.5     129     42.6    59.7         7±7                                          8.6±1.2                                 -0.9 ±0.1[\*](#T2FN2){ref-type="table-fn"}    34.2[\*](#T2FN2){ref-type="table-fn"}   33±6                                         95±18            -1.6 ±0.3[\*](#T2FN2){ref-type="table-fn"}
  5 mcg ExBID                              24.0            125                              40.8     61.6    6±5     8.5±1.1      -0.5 ±0.1[\*](#T2FN2){ref-type="table-fn"}   26.7[\*](#T2FN2){ref-type="table-fn"}   303±6                                         95±22                                   -0.9±0.3                                                      
  PBO                                      39.8            123                              37.4     66.7    6±5     8.7±1.2      0.1±0.1                                      7.7                                     34±5                                          99±18                                   -0.6±0.3                                                      
  Buse 2007 \[[@R93]\]                     ExBID           MET +/or SFU                     45.7     521     41      74           8±6                                          8.4±1.1                                 -1.1±0.1                                      50                                      34±6                                         99±20            -4.7±0.3
  Davies 2009 \[[@R94]\]                   ExBID           MET +/or SFU +/or TZD            16.1     118     29.7    NG           9±5                                          8.7±0.7                                 -1.25± 0.09                                   NG                                      35±6                                         101.4±19.8       -2.7 ±0.3[\*](#T2FN2){ref-type="table-fn"}
  Glarg                                    10.3            117                              33.6     NG      8±4     8.5±0.7      -1.26 ±0.09                                  NG                                      34±5                                          97.6±16.4                               3.0±0.3                                                       
  DeFronzo 2005 \[[@R95]\]                 ExBID           MET                              17.7     113     39.8    79.6         5±5                                          8.2±1.0                                 -0.8 ±0.1[\*](#T2FN2){ref-type="table-fn"}    46[\*](#T2FN2){ref-type="table-fn"}     34±6                                         101±20           -2.8 ±0.5[\*](#T2FN2){ref-type="table-fn"}
  5 mcg ExBID                              18.2            110                              48.2     77.3    6±6     8.3±1.1      -0.4 ±0.1[\*](#T2FN2){ref-type="table-fn"}   32[\*](#T2FN2){ref-type="table-fn"}     34±6                                          100±22                                  -1.6 ±0.4[\*](#T2FN2){ref-type="table-fn"}                    
  PBO                                      21.2            113                              40.7     72.6    7±6     8.2±1.0      0.1±0.1                                      13                                      34±6                                          100±19                                  -0.3±0.3                                                      
  Derosa 2010 \[[@R96]\]                   ExBID           MET                              6.3      63      52.4    100          NG                                           8.8±0.7                                 -1.5                                          NG                                      29±2                                         82.0±8.3         -8.0
  Gli                                      12.3            65                               49.2     100     NG      8.9±0.8      -1.8                                         NG                                      29±1                                          82.4±9.1                                +4.3                                                          
  Derosa 2011 \[[@R97]\]                   ExBID           MET                              8.8      57      50.9    100          NG                                           8.7±0.7                                 -1.2                                          NG                                      28±1                                         80.2±7.5         -5.1
  Gli                                      9.3             54                               51.9     100     NG      8.8±0.8      -1.4                                         NG                                      29±1                                          81.4±8.1                                -0.9                                                          
  Forti 2008 \[[@R98]\]                    ExBID at B, D   MET ± SFU ± TZD                  11.1     190     58.4    41.0         9±6                                          8.4±0.9                                 -1.2±0.1                                      45.1                                    31±4                                         82.7±16.1        -1.3±0.2
  ExBID at L, D                            16.0            187                              51.3     45.0    8±6     8.5±1.0      -1.1±0.1                                     32.6                                    31±4                                          81.8±14.2                               -1.1±0.2                                                      
  Gallwitz 2011 \[[@R99]\]                 ExBID           MET                              25.4     181     NG      NG           5±4                                          7.9±0.8                                 -1.00                                         49.2                                    33±4                                         NG               -4.1 ±0.2[\*](#T2FN2){ref-type="table-fn"}
  Aspart                                   20.8            173                              NG       NG      5±5     7.9±0.9      -1.14                                        56.6                                    33±4                                          NG                                      1.0± 0.2                                                      
  Gao 2009 \[[@R100]\]                     ExBID           MET ± SFU                        17.5     234     52      0            8±6                                          8.3±1.0                                 -1.2[\*](#T2FN2){ref-type="table-fn"}         48[\*](#T2FN2){ref-type="table-fn"}     26±3                                         69.6±11.2        -1.2[\*](#T2FN2){ref-type="table-fn"}
  PBO                                      10.3            232                              59       0       8±5     8.3±1.0      -0.4                                         17                                      26±3                                          67.9±11.0                               -0.1                                                          
  Gill 2010 \[[@R101]\]                    ExBID           MET +/or TZD                     21.4     28      32      86           7±4                                          7.5±0.9                                 NG                                            NA                                      30±3                                         91.6±15.2        -1.8 ±0.4[\*](#T2FN2){ref-type="table-fn"}
  PBO                                      11.5            26                               58       96      6±4     7.1±0.7      NG                                           NA                                      30±4                                          85.9±12.2                               -0.3±0.4                                                      
  Heine 2005 \[[@R102]\]                   ExBID           MET + SFU                        19.1     282     45.0    79.8         10±6                                         8.2±1.0                                 -1.1                                          46                                      31±4                                         87.5±16.9        -2.3[\*](#T2FN2){ref-type="table-fn"}
  Glarg                                    9.4             267                              43.4     80.5    9±6     8.3±1.0      -1.1                                         48                                      31±5                                          88.3±17.9                               +1.8                                                          
  Kadowaki 2009 \[[@R103]\]                ExBID           SFU ±MET or ±TZD                 16.2     38      37.8    0            10± 6                                        7.9±0.9                                 -1.4 ±0.1[\*](#T2FN2){ref-type="table-fn"}    79.4[\*](#T2FN2){ref-type="table-fn"}   26±5                                         70.3±15.9        -1.3±0.3
  5.0 mcg ExBID                            10.8            37                               32.4     0       11± 6   7.9±0.8      -1.2 ±0.1[\*](#T2FN2){ref-type="table-fn"}   71.4[\*](#T2FN2){ref-type="table-fn"}   25±3                                          65.6±9.8                                -0.2±0.3                                                      
  2.5 mcg ExBID                            8.1             38                               29.7     0       15±11   8.0±0.8      -0.9 ±0.1[\*](#T2FN2){ref-type="table-fn"}   50.0[\*](#T2FN2){ref-type="table-fn"}   24±3                                          64.9±11.6                               -0.08±0.2                                                     
  PBO                                      2.5             40                               25.0     0       12±6    8.1±0.7      0.02± 0.1                                    5.1                                     26±5                                          71.1±14.0                               -0.7±0.2                                                      
  Kadowaki 2011 \[[@R104]\]                ExBID           SFU±MET or SFU±TZD               27.4     72      31.9    0            12±7                                         8.2±1.0                                 -1.6[\*](#T2FN2){ref-type="table-fn"} ±0.1    71.0[\*](#T2FN2){ref-type="table-fn"}   26±4                                         69.1±11.2        -1.5 ±0.3[\*](#T2FN2){ref-type="table-fn"}
  5 mcg ExBID                              9.7             72                               31.9     0       12±6    8.3±0.8      -1.3 ±0.1[\*](#T2FN2){ref-type="table-fn"}   67.1[\*](#T2FN2){ref-type="table-fn"}   25±4                                          67.0±11.5                               -0.4±0.3                                                      
  PBO                                      5.7             35                               31.4     0       12±7    8.1±0.9      -0.3±0.2                                     15.2                                    26±4                                          70.3±13.3                               -0.5±0.4                                                      
  Kendall 2005 \[[@R105]\]                 ExBID           MET + SFU                        17.8     241     40.7    66.4         9±6                                          8.5±1.1                                 -0.8 ±0.1[\*](#T2FN2){ref-type="table-fn"}    30[\*](#T2FN2){ref-type="table-fn"}     34±6                                         98±21            -1.6 ±0.2[\*](#T2FN2){ref-type="table-fn"}
  5 mcg ExBID                              15.9            245                              40.8     69.0    9±6     8.5±1.0      -0.6 ±0.1[\*](#T2FN2){ref-type="table-fn"}   24[\*](#T2FN2){ref-type="table-fn"}     33±6                                          97±19                                   -1.6 ±0.2[\*](#T2FN2){ref-type="table-fn"}                    
  PBO                                      23.9            247                              44.1     68.4    9±6     8.5±1.0      0.2±0.1                                      7                                       34±5                                          99±19                                   -0.9±0.2                                                      
  Klonoff 2008 \[[@R106]\]                 ExBID           MET, + SFU                       58.8     527     36      83           8±6                                          8.2±1.0                                 -1.0±0.1                                      46                                      34±5                                         99±18            -5.3±0.4
  Liukus 2010 \[[@R107]\]                  ExBID           TZD ± MET                        14       111     40      57           6±4                                          8.2±0.9                                 -0.8 ±0.2[\*](#T2FN2){ref-type="table-fn"}    49                                      34±6                                         94.5±17.8        -1.4±0.6
  PBO                                      7               54                               43       61      6±5     8.3±0.9      -0.1±0.2                                     36                                      33±5                                          92.6±18.0                               -0.8±0.7                                                      
  Moretto 2008 \[[@R108]\]                 ExBID           D/E                              14       78      38      72           2±3                                          7.8±1.0                                 -0.9 ±0.1[\*](#T2FN2){ref-type="table-fn"}    46[\*](#T2FN2){ref-type="table-fn"}     31±5                                         86±16            -3.1 ±0.3[\*](#T2FN2){ref-type="table-fn"}
  5 mcg ExBID                              13              77                               48       65      2±3     7.9±1.0      -0.7 ±0.1[\*](#T2FN2){ref-type="table-fn"}   48[\*](#T2FN2){ref-type="table-fn"}     32±5                                          85±15                                   -2.8 ±0.3[\*](#T2FN2){ref-type="table-fn"}                    
  PBO                                      12              77                               45       66      1±2     7.8±1.0      -0.2±0.1                                     29                                      32±5                                          86±16                                   -1.4±0.3                                                      
  Nauck 2007 \[[@R109]\]                   ExBID           MET + SFU                        21.3     253     47      NG           10±6                                         8.6±1.0                                 -1.0±0.1                                      32[\*](#T2FN2){ref-type="table-fn"}     31±4                                         85.5±15.7        -2.5 ±0.2[\*](#T2FN2){ref-type="table-fn"}
  Aspart                                   10.1            248                              51       NG      10± 6   8.6±1.1      -0.9±0.1                                     24                                      30±4                                          83.4±15.6                               2.9±0.2                                                       
  Ratner 2006 \[[@R110]\]                  ExBID           MET                              39       150     31      86           5±5                                          8.1±1.0                                 -1.3±0.1                                      59                                      34±6                                         102±21           -5.3±0.8
  Riddle 2006 \[[@R111]\]                  ExBID           SFU ± MET                        45       401     39      75           8±6                                          8.4±1.0                                 -1.0±0.1                                      44                                      34±6                                         99±21            -4.0±0.3
  Zinman 2007 \[[@R112]\]                  ExBID           TZD ± MET                        28.9     121     46.3    85.1         7±5                                          7.9±0.9                                 -0.9 ±0.1[\*](#T2FN2){ref-type="table-fn"}    62[\*](#T2FN2){ref-type="table-fn"}     34±5                                         97.5±18.8        -1.8 ±0.3[\*](#T2FN2){ref-type="table-fn"}
  PBO                                      14.3            112                              42.9     82.1    8±6     7.9±0.8      0.1±0.1                                      16                                      34±5                                          96.9±19.0                               -0.2±0.3                                                      
  **Exenatide QW**                                                                                                                                                                                                                                                                                                                                                         
  Bergenstal 2010 \[[@R113]\] DURATION-2   ExQW            MET                              20.6     160     44      33           6±5                                          8.6±1.2                                 -1.5[\*](#T2FN2){ref-type="table-fn"}         \~58[\*](#T2FN2){ref-type="table-fn"}   32±5                                         89±20            -2.3[\*](#T2FN2){ref-type="table-fn"}
  100 mg SITA                              13.3            166                              48       30      5±4     8.5±1.2      -0.9                                         \~30                                    32±5                                          87±20                                   -0.8                                                          
  45 mg PIO                                20.6            165                              52       39      6±5     8.5±1.1      -1.2                                         \~42                                    32±6                                          88±20                                   2.8                                                           
  Blevins 2011 \[[@R114]\] DURATION-5      ExQW            D/E, MET, SFU, TZD or any comb   15.5     129     40      63           7±5                                          8.5±1.1                                 -1.6 ±0.1[\*](#T2FN2){ref-type="table-fn"}    58.1[\*](#T2FN2){ref-type="table-fn"}   34±6                                         97.0±20.7        -2.3±0.4
  ExBID                                    22.8            123                              45       55      7±5     8.4±1.2      -0.9±0.1                                     30.1                                    33±5                                          94.3±18.9                               -1.4±0.4                                                      
  Buse 2010 \[[@R115]\] DURATION-1         ExQW            D/E, MET, SFU, TZD or 2 OAD      19       148     43      83           7±6                                          8.3±1.0                                 -2.0                                          71                                      35±5                                         103±19           -4.1
  ExBID then ExQW                          18              147                              47       74      6±5     8.2±0.9      -2.0                                         71                                      35±5                                          102±20                                  -4.5                                                          
  Buse 2011^1^                             ExQW            MET, SFU, TZD, or any comb       13.2     461     44.9    83.3         8±6                                          8.4±1.0                                 -1.3                                          52.3                                    32±6                                         90.9±19.5        -2.7
  LIRA                                     13.1            450                              45.6     81.8    9±7     8.4±1.0      -1.5                                         60.2                                    32±5                                          91.1±19.1                               -3.6                                                          
  Diamant 2010 \[[@R116]\]                 ExQW            MET ± SFU                        10.3     233     48      82           8±6                                          8.3±1.1                                 -1.5 ±0.1[\*](#T2FN2){ref-type="table-fn"}    60[\*](#T2FN2){ref-type="table-fn"}     32±5                                         91.2±18.6        -2.6 ±0.2[\*](#T2FN2){ref-type="table-fn"}
  Glarg                                    6.3             223                              45       85      8±6     8.3±1.0      -1.3±0.1                                     48                                      32±5                                          90.6±16.4                               1.4±0.2                                                       
  Drucker 2008 \[[@R117]\]                 ExQW            D/E, MET, SFU, TZD or 2 OAD      13.5     148     45.0    83           7±6                                          8.3±1.0                                 -1.9 ±0.1[\*](#T2FN2){ref-type="table-fn"}    77[\*](#T2FN2){ref-type="table-fn"}     35±5                                         102±19           -3.7±0.5
  ExBID                                    11.6            147                              49.0     73      6±5     8.3±1.0      -1.5±0.1                                     61                                      35±5                                          102±21                                  -3.6±0.5                                                      
  MacConell 2011^2^                        ExQW            D/E, MET, SFU, TZD or 2 OAD      34       295     NG      NG           7±5                                          8.2±1.0                                 -1.6                                          57                                      NG                                           101±18           -2.3
  Russell-Jones 2012 \[[@R118]\]           ExQW            D/E                              15.3     248     44      68.1         3±3                                          8.5±1.2                                 -1.5±0.1                                      63                                      31±5                                         88±19            -2.0±0.2
  MET                                      13.4            246                              37       65.0    3±4     8.6±1.2      -1.5±0.1                                     55                                      31±6                                          86±20                                   -2.0±0.2                                                      
  PIO                                      18.4            163                              41       67.5    3±4     8.5±1.2      -1.6±0.1                                     61                                      31±5                                          86±18                                   1.5±0.3                                                       
  SITA                                     14.1            163                              42       69.3    3±4     8.5±1.3      -1.2±0.1                                     43                                      32±5                                          89±19                                   -0.8±0.3                                                      
  Taylor 2011 \[[@R119]\]                  ExQW            D/E, MET, SFU, TZD or 2 OAD      27       295     47      79           7±5                                          8.2±1.0                                 -1.7±0.1                                      60                                      35±5                                         101±19           -2.6±0.5
  Wysham 2011 \[[@R120]\]                  ExQW            MET                              35.6     160     43      32           6±5                                          8.6±1.2                                 -1.6±0.1                                      58                                      32±5                                         90±19            -1.8±0.5
  SITA then ExQW                           21.7            166                              42       35      6±5     8.5±1.1      -1.8±0.5                                     53                                      32±5                                          88±21                                   -1.1±0.3                                                      
  PIO then EQW                             39.4            165                              49       39      6±5     8.4±1.0      -1.6±0.1                                     59                                      32±5                                          86±21                                   -3.0±0.3                                                      

Note: when \'ExBID\' is listed without dose, dose was 10 mcg BID. When ExQW listed without dose, dose was 2 mg.

p\<0.05 improvement in HbA~1c~ or weight versus control group.

Portions of table adapted from: Aroda V, Henry R, Han J, *et al.* A meta-analysis and systematic review of the efficacy of GLP-1 receptor agonists and DPP-4 inhibitors. Clin Ther. 2012;34:1247-58.e22

###### 

Overview of Nausea, Vomiting, Hypoglycemia, and Selected Treatment-Emergent Adverse Events from Phase 3 Exenatide Clinical Trials

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Citation                                         Treatment                              Nausea (%)         Vomiting (%)   Hypo (%)   Major/ Severe Hypo?                                         Other Relevant Observations
  ------------------------------------------------ -------------------------------------- ------------------ -------------- ---------- ----------------------------------------------------------- --------------------------------------------------------------
  **EXENATIDE BID CLINICAL TRIALS**                                                                                                                                                                

  Bergenstal 2009 \[[@R86]\]                       ExBID+MET+SFU                          29                 NG             29         No                                                          1.28 hypo/subj-y.

  Aspart QD+MET+SFU                                9                                      NG                 56             3.2%       4.02 hypo/subj-y. P=0.0013 vs Ex                            

  Aspart BID+MET+SFU                               8                                      NG                 61             4.8%       5.25 hypo/subj-y. P\<0.0001 vs Ex                           

  Blonde 2006 \[[@R87]\]                           ExBID+MET +/or SFU                     14-29              NG             7-12       0.7%                                                        The severe hypo event occurred in a patient treated with SFU

  Bunck 2009 \[[@R88]\]                            ExBID+MET                              50                 NG             8.3        No                                                          1 pancreatitis, resolved after Ex stopped

  Glarg+MET                                        NG                                     NG                 24.2           No                                                                     

  Bunck 2011 \[[@R89]\]                            ExBID+MET                              38.1               9.5            19.0       No                                                          

  Glarg+MET                                        NG                                     8.0                28.0           No                                                                     

  Buse 2011 \[[@R90]\]                             ExBID+Glarg                            41                 18             25.0       No                                                          1.4 hypo/subj-y\
                                                                                                                                                                                                   Nocturnal: 17% hypo

  PBO+Glarg                                        8                                      4                  29.0           1%         1.2 hypo/subj-y. P=0.49 vs Ex\                              
                                                                                                                                       Nocturnal: 26% hypo                                         

  Buse 2009 \[[@R91]\]                             ExBID+MET±SFU                          28.0               9.9            34.5       0.9%                                                        2.6 minor hypo/subj-y. Major hypo had SFU

  LIRA+MET±SFU                                     25.5                                   6.0                26.0           No         1.9 minor hypo/subj-y. P=0.0131 vs Ex 1 mild pancreatitis   

  Buse 2004 \[[@R92]\]                             ExBID+MET +/or SFU                     51                 13             36         No                                                          

  5 mcg ExBID+MET +/or SFU                         39                                     10                 14             No                                                                     

  PBO+MET +/or SFU                                 7                                      2                  3              No                                                                     

  Buse 2007 \[[@R93]\]                             ExBID+MET +/or SFU                     8-39               NG             \<1-13     0.2%                                                        1 severe hypo in 1010 subj-y

  Davies 2009 \[[@R94]\]                           ExBID+MET+/or SFU+/or TZD              48.3               NG             50.0       4.2%                                                        Nocturnal hypo: 11.9%.

  Glarg+MET+/or SFU+/or TZD                        2.6                                    NG                 59.6           5.3%       Nocturnal hypo: 29.8%. P=0.001 vs Ex                        

  DeFronzo 2005 \[[@R95]\]                         ExBID+MET                              45                 12             5          No                                                          

  5 mcg ExBID+MET                                  36                                     11                 5              No                                                                     

  PBO+MET                                          23                                     4                  5              No                                                                     

  Derosa 2010 \[[@R96]\]                           ExBID+MET                              NG                 NG             0          NG                                                          

  Glibenclamide+MET                                NG                                     NG                 4.6            NG                                                                     

  Derosa 2011 \[[@R97]\]                           ExBID+MET                              NG                 NG             0          NG                                                          

  Glibenclamide+MET                                NG                                     NG                 5.6            NG                                                                     

  Forti 2008 \[[@R98]\]                            ExBID at B/D+MET± SFU±TZD              22.6               10.0           NG         4.2%                                                        5.21 hypo/subj-y. P=0.393 vs Ex L/D

  ExBID at L/D+MET± SFU± TZD                       25.1                                   10.2               NG             0.5%       6.51 hypo/subj-y                                            

  Gallwitz 2011 \[[@R99]\]                         ExBID+MET                              18.8               9.9            8.0        No                                                          Nocturnal hypo: 3.9%

  Aspart+MET                                       NG                                     NG                 20.5           No         Nocturnal hypo: 7.0%                                        

  Gao 2009 \[[@R100]\]                             ExBID+MET±SFU                          25.5               15.8           35.5       0.9%                                                        4.4 hypo/subj-y.\
                                                                                                                                                                                                   MET only: 1.8 hypo/subj-y\
                                                                                                                                                                                                   MET+SFU: 4.7 hypo/subj-y

  PBO+MET±SFU                                      0.9                                    0                  9.0            0.4%       0.5 hypo/subj-y\                                            
                                                                                                                                       MET only: 0.22 hypo/subj-y\                                 
                                                                                                                                       MET+SFU: 0.54 hypo/subj-y                                   

  Gill 2010 \[[@R101]\]                            ExBID+MET +/or TZD                     36                 NG             7          No                                                          

  PBO+MET +/or TZD                                 19                                     NG                 4              No                                                                     

  Heine 2005 \[[@R102]\]                           ExBID+MET+SFU                          57.1               17.4           NG         1.4%                                                        7.3 hypo/subj-y.\
                                                                                                                                                                                                   Nocturnal hypo: 21%; 0.9 hypo/subj-y

  Glarg+MET+SFU                                    8.6                                    3.7                NG             1.5%       6.3 hypo/subj-y.\                                           
                                                                                                                                       Nocturnal hypo: 43%; 2.4 hypo/subj-y                        

  Kadowaki 2009 \[[@R103]\]                        ExBID+SFU±MET, +SFU±TZD                35.1               8.1            54.1       No                                                          

  5 mcg ExBID+SFU±MET, +SFU±TZD                    8.1                                    13.5               43.2           No                                                                     

  2.5 mcg ExBID+SFU± MET, +SFU±TZD                 10.8                                   5.4                27.0           No                                                                     

  PBO+SFU±MET, +SFU±TZD                            0                                      0                  10.0           No                                                                     

  Kadowaki 2011 \[[@R104]\]                        ExBID+SFU, +SFU+MET, +SFU+TZD          36.1               16.7           58.3       No                                                          

  5 mcg ExBID+SFU, +SFU+MET, +SFU+TZD              25.0                                   4.2                51.4           No                                                                     

  PBO+ExBID+SFU, +SFU+MET, +SFU+TZD                8.6                                    2.9                22.9           No                                                                     

  Kendall 2005 \[[@R105]\]                         ExBID+MET+SFU                          48.5               13.7           27.8       No                                                          Lower hypo incidence in SFU MIN group

  5 mcg ExBID+MET+SFU                              39.2                                   14.7               19.2           4.1%                                                                   

  PBO+MET+SFU                                      20.6                                   4.5                12.6           No                                                                     

  Klonoff 2008 \[[@R106]\]                         ExBID+MET+SFU                          59.0               NG             40.0       0.2%                                                        All severe hypo events occurred in patients treated with SFU

  Liukus 2010 \[[@R107]\]                          ExBID+TZD±MET                          12                 8              4.0        No                                                          

  PBO+TZD±MET                                      2                                      0                  2.0            No                                                                     

  Moretto 2008 \[[@R108]\]                         ExBID                                  13                 4              4          No                                                          0.52 hypo/subj-y

  5 mcg ExBID                                      3                                      4                  5              No         0.21 hypo/subj-y                                            

  PBO                                              0                                      0                  1              No         0.03 hypo/subj-y. P=0.014 vs Ex                             

  Nauck 2007 \[[@R109]\]                           ExBID+MET+SFU                          33.2               15.0           NG         No                                                          4.7±0.7 hypo/subj-y\
                                                                                                                                                                                                   Nocturnal hypo: 17%.

  Aspart+MET+SFU                                   0.4                                    3.2                NG             No         5.6±0.7 hypo/subj-y\                                        
                                                                                                                                       Nocturnal hypo: 25%; P\<0.038 vs Ex                         

  Ratner 2006 \[[@R110]\]                          ExBID+MET                              14-33              1-5            NG         No                                                          

  Riddle 2006 \[[@R111]\]                          ExBID+SFU±MET                          14-27              NG             8-15       1.0%                                                        

  Zinman 2007 \[[@R112]\]                          ExBID+TZD±MET                          39.7               13.2           10.7       No                                                          

  PBO+TZD±MET                                      15.2                                   0.9                7.1            No                                                                     

  **EXENATIDE QW CLINICAL TRIALS**                                                                                                                                                                 

  Bergenstal 2010 \[[@R113]\]                      ExQW+MET                               24                 11             1          No                                                          

  SITA+MET                                         10                                     2                  3              No                                                                     

  PIO+MET                                          5                                      3                  1              No         2 cases of pancreatitis                                     

  Blevins 2011 \[[@R114]\]                         ExQW+D/E, MET, SFU, TZD or any combo   14.0               4.7            3.9        No                                                          All hypo events occurred in patients treated with SFU\
                                                                                                                                                                                                   1 case pancreatitis: resolved while taking ExQW.

  ExBID+D/E, MET, SFU, TZD or any combo            35.0                                   8.9                3.3            No         All hypo events occurred in patients treated with SFU       

  Buse 2010 \[[@R115]\]                            ExQW+D/E, MET, SFU, TZD or 2 OADs      7.0                6.3            NG         No                                                          All hypo events occurred in patients treated with SFU\
                                                                                                                                                                                                   Wk 30-52: 10.2% hypo

  ExBID then ExQW, +D/E, MET, SFU, TZD or 2 OADs   7.7                                    4.6                NG             No         All hypo events occurred in patients treated with SFU\      
                                                                                                                                       Wk 30-52: 8.0% hypo                                         

  Buse 2011^1^                                     ExQW+MET, SFU, TZD or any comb         9.3                3.7            10.8       No                                                          

  LIRA+MET, SFU, TZD or any comb                   20.4                                   10.7               8.9            No                                                                     

  Diamant 2010 \[[@R116]\]                         ExQW+MET±SFU                           13                 4              8          No                                                          

  Glarg+MET±SFU                                    1                                      1                  26             No         Hypo with MET: p\<0.0001 vs Ex+MET\                         
                                                                                                                                       Hypo with MET+SFU: p=0.0009 vs Ex+MET+SFU\                  
                                                                                                                                       [Nocturnal hypo]{.ul}\                                      
                                                                                                                                       Hypo with MET: p=0.028 vs Ex+MET\                           
                                                                                                                                       Hypo with MET+SFU: p=0.0005 vs Ex+MET+SFU                   

  Drucker 2008 \[[@R117]\]                         ExQW+D/E, MET, SFU, TZD or 2 OADs      26.4               10.8           5.4        No                                                          Hypo with SFU: 14.5% vs 0% without SFU

  ExBID then ExQW, +D/E, MET, SFU, TZD or 2 OADs   34.5                                   18.6               6.1            No         Hypo with SFU: 15.4% hypo vs 1.1% without SFU               

  MacConell 2011^2^                                ExQW+D/E, MET, SFU, TZD or 2 OADs      16 (wks 30- 156)   NG             NG         No                                                          

  Russell-Jones 2012 \[[@R118]\]                   ExQW                                   11.3               4.8            5.2        No                                                          

  MET                                              6.9                                    3.3                4.1            No                                                                     

  PIO                                              4.3                                    3.1                3.7            No                                                                     

  SITA                                             3.7                                    1.8                3.1            No                                                                     

  Taylor 2011 \[[@R119]\]                          ExQW+D/E, MET, SFU, TZD or 2 OADs      12\*               9\*            6.6\*      No                                                          \*Wk 30-104\
                                                                                                                                                                                                   Hypo with SFU: 94% (16/17 subj)

  Wysham 2011 \[[@R120]\]                          ExQW+MET                               5.0\*\*            5.0\*\*        1\*\*      No                                                          \*\*Wk 26-52

  SITA then ExQW, +MET                             10.8\*\*                               3.8\*\*            2\*\*          No         \*\*Wk 26-52                                                

  PIO then ExQW, +MET                              9.6\*\*                                2.6\*\*            1\*\*          No         \*\*Wk 26-52                                                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: when \'ExBID\' is listed without dose, dose was 10 mcg BID. When ExQW listed without dose, dose was 2 mg.

Abbreviations: Aspart insulin aspart; B, breakfast; BID, twice daily; D, dinner; Ex, exenatide; GLARG, insulin glargine; Hypo, hypoglycemic events; hypo/subj-y, number of hypoglycemic events per subject year; L, lunch; MET, metformin; MIN, minimum; Lira, liraglutide; NG, not given; PBO, placebo; PIO, pioglitazone; QW, once weekly; Sita, sitagliptin; Subj, subject; SFU, sulfonylurea; TZD, thiazolidinedione; vs, versus; Wk, week; Y, year.
